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Stroke is an important cause of death and disability in sub-Saharan Africa. 
Recombinant tissue plasminogen activator (tPA) thrombolysis is effective in treating 
acute ischaemic stroke, but may not be a viable option in developing countries.  
 
Methods 
This prospective observational study was designed to assess the short-term 
outcomes and safety of tPA for the treatment of stroke at Groote Schuur Hospital. 
Data was collected from January 2000 to February 2012, and included patients with 
a clinical diagnosis of acute stroke with onset of stroke symptoms within 4.5 hours of 
receiving thrombolysis. Exclusion criteria were based on the National Institute of 
Neurological Disorders and Stroke (NINDS) rt-PA trial protocol (upper age limit was 
75 years). Primary outcomes were the proportion of patients achieving significant 
early neurological recovery defined as an improvement of 4 or more points on the 
National Institutes of Health stroke scale (NIHSS) score and functional independence 
defined as a modified Rankin score of 2 or less at discharge. The primary safety 
measures were the rates of symptomatic intracranial haemorrhage (SICH) and death.  
 
Results 
From January 2000 to February 2011 42 patients were thrombolysed, with a mean 
time to tPA infusion of 160 minutes (standard deviation (SD) 50; range 60 - 270). By 
discharge the median NIHSS score fell from 14 (interquartile range (IQR) 10.5 - 17) to 
7.5 (IQR 1 - 15); 28 (66.7%) achieved significant neurological improvement, and 17 
(40.5%) were functionally independent. Two patients (4.8%) suffered SICH and there 
were 3 (7.1%) deaths.  
 
Conclusion 
Thrombolysis in routine clinical practice in a South African setting has similar safety 
and early efficacy outcomes to controlled trials and open-label studies in developing 
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1. STROKE AS A CAUSE OF DISABILITY AND DEATH IN THE DEVELOPING WORLD 
1.1 Global burden 
1.1.1 According to data from the Global Burden of Disease study, of the 5.4 million 
individuals who died of stroke in 2001, fewer than 1.0 million lived in high-income 
countries. Cerebrovascular disease was the second leading cause of death in low-and-
middle-income countries, accounting for 9.5% of the total, similar to high-income 
countries where it caused 9.9% of all deaths [Lopez, 2006]. 
 
1.2 Prevalence 
1.2.1 Although mortality in sub-Saharan Africa is dominated by infectious and perinatal 
diseases, it is estimated that 355 000 stroke deaths (3% of all deaths) occurred in this 
region in 2001 [Connor, 2007]. That year the prevalence of stroke ranged from 0.07 to 
0.3% in a systematic review of published articles from sub-Saharan Africa [Dalal, 2011]. 
This data is supported by Southern African Stroke Prevention Initiative (SASPI) study of a 
rural South African community in Agincourt, Limpopo, where stroke prevalence in 2001 
was calculated at 290 per 100000 (95% CI 238 to 343) for those over the age of 15 years, 
with a steep age gradient. The age-specific prevalence of 598 per 100 000 was similar to 
that recorded in New Zealand (615 per 100000) [Connor, 2004].  
 
1.2.2 The Agincourt study site was established in 1992 in order to examine the burden of 
disease amongst rural black South Africans. Investigators performed an annual census of 
the community as well as verbal autopsies to determine contributors to mortality. Over 
the period 1992 to 1995, the proportionate mortality rate from stroke was 5.5% of all 
deaths. Stroke was the commonest cause of death in the age 55 to 74 years group 
(11%), and the second most common cause of death in the age 35 to 54 years group 
(10%) and over age 75 years group (6%). Stroke was responsible for 22% of deaths due 
to non-communicable disease [Kahn, 1999]. When extended to 2005 the age-
standardised deaths due to all non-communicable diseases increased (1.15 [0.99 – 1.33]; 
p = 0.066) along with the massive 6-fold rise in deaths due to infectious causes. In this 
cohort deaths due to stroke, ischaemic heart disease, and hypertension increased by 













the rise in mortality due to HIV and TB, non-communicable disease remains a growing 
and important cause of disease burden.  
 
1.3 Morbidity 
1.3.1 Morbidity and mortality of stroke in sub-Saharan Africa is high. Sixty-six percent of 
stroke survivors from the Agincourt district site required assistance with at least one 
activity of daily living, equating to a prevalence of 200/100000 [Connor, 2004]. This is 
much higher compared to stroke survivors from a New Zealand community, only 22% of 
whom required help with self-care activities [Bonita, 1997]. In three Tanzanian sites the 
15 to 64 years age-adjusted stroke mortality rates were statistically higher than in 
England and Wales [Walker, 2000].  
 
1.3.2 An observational study performed at a rural site in Kwazulu-Natal showed an overall 
mortality of 30% at 3 months after stroke, much higher than the all stroke fatality of 20% 
in high-income countries. Most of the strokes resulted in severe disability, placing a 
burden on family carers in a poor socio-economic environment [Wasserman, 2009].  
 
1.4 Emerging epidemic 
1.4.1 Although the overall prevalence of stroke is lower than in high-income regions, 
disabling stroke prevalence may be at least as high in sub-Saharan Africa [Connor, 2007]. 
This is consistent with a so-called bipolar health transition where infectious and non-
communicable diseases co-exist and both contribute significantly to chronic illness 
[Frenk, 1989]. There is evidence that hypertension and obesity are highly prevalent in 
rural and urban areas in South Africa [Rayner, 2010]. This, together with increasing rates 
of communicable disease, represents the early phase of a health transition in the region.  
A clinical survey using blood pressure, body mass index and ankle brachial index 
measurements demonstrated a high prevalence of sub-clinical atheroma and other 
vascular risk factors in adults from the rural Agincourt district [Thorogood, 2007], an 
indication of progression to later phases of the transition characterised by complications 
of atherosclerotic disease. South Africa may thus be facing an emerging epidemic of 














2. MODELS OF CARE 
2.1.1 A number of studies have been conducted in South Africa with the aim of identifying 
factors to be included in a model of stroke care for both rural and urban communities. 
Prevention strategies are paramount and need to be developed in order to deal with the 
risk factors that form the basis of the emerging epidemic of non-communicable diseases. 
But there is currently a lack of public health education in rural areas with a high 
prevalence of hypertension and poor blood pressure control in stroke survivors, as well 
as limited use of anti-hypertensives and medication for secondary prevention 
[Wasserman, 2009]. Contributing factors include limited access to health care facilities 
because of transport costs and poor infrastructure, and lack of basic equipment 
[Thorogood, 2004]. Hypertension is also poorly detected and managed in South African 
urban areas [Rayner, 2010].  
 
2.1.2 There is robust evidence that the management of patients in a dedicated stroke unit 
reduces mortality and disability after acute stroke. Stroke units are dedicated and 
geographically defined areas in a hospital that provide care for the acute and post-acute 
phase of stroke. They comprise specialist medical and nursing staff that follows 
established protocols for management of acute stroke and its complications and work 
within the framework of a multidisciplinary team including dieticians, occupational and 
physiotherapists and social workers [Bryer, 2010].  
 
2.1.3 The latest Cochrane review of stroke unit trials published in 2007 showed a 14% 
reduction in death (OR 0.86; 95% CI 0.76 to 0.98; p = 0.02) at a median time of one year 
after acute stroke. This analysis also demonstrated that patients treated in stroke units 
are more likely to be alive and independent (OR 0.82; 95% CI 0.73 to 0.92; p = 0.001) and 
to return home (OR 0.82; 95% CI 0.73 to 0.92; p = 0.0006) compared with controls from 
31 trials involving almost 7000 patients. Length of stay was not significantly increased 
[Stroke Unit Trialists’ Collaboration, 2007].  
 
2.1.4 These results were replicated in a systematic review of observational studies of 
stroke unit implementation in routine clinical practice, which showed a comparable 













or dependency (OR 0.87, 95% CI 0.80 to 0.95; p = 0.002) at one year [Seenan, 2007]. A 
general review of effectiveness of acute stroke interventions published in 1999 strongly 
supported the implementation of stroke units because of its suitability as a model to 
manage all patients with stroke. In this analysis, organised care in a stroke unit was 
estimated to reduce death and dependency at one year after stroke from 62.0% to 
56.4% (a relative risk reduction of 9% and an absolute risk reduction of 5.6%); translating 
into a NNT of 18. The impact of stroke units on a population depends on their 
accessibility, and this varies between countries. By treating 80% of stroke patients from 
a population of 1 million people in stroke units, approximately 107 fewer deaths or 
dependent survivors would result each year. Furthermore, assuming no impact on 
length of stay, the cost of treating patients in stroke units may be similar to routine care 
[Hankey, 1999].  
 
2.1.5 There are few dedicated stroke units in the South African public health sector, with 
only two in the Western Cape. A study from one of these sites at a secondary-level 
hospital demonstrated improved outcomes in patients with acute stroke who were 
managed by a multidisciplinary team. Despite an increased length of stay by 2 days (6.8 
versus 5.1 days before the establishment of the stroke unit), the authors demonstrated 
improved stroke care without the requirement of additional funding and staff [de 
Villiers, 2009]. The South African Stroke Society recommends that all acute stroke 
patients should be managed in a stroke unit and that they should be incorporated into 
existing models of stroke care [Bryer, 2010].   
 
3. THROMBOLYSIS FOR ACUTE ISCHAEMIC STROKE 
3.1 Early trials 
3.1.1 Optimal acute stroke management requires rapid pre- and in-hospital assessment 
and medical treatment with a focus on maintenance of normal homeostasis [Leys, 2007; 
Bryer, 2010]. However, this approach is purely supportive, and a specific intervention for 
acute stroke has been sought for decades. It was hypothesised that early recanalisation 
of an occluded artery may assist recovery of reversibly ischaemic tissue. Thrombolytic 
agents were identified as candidates for this on the basis of their potential to dissolve 













administered early [Fletcher, 1976]. The first trials testing this were conducted with 
streptokinase. Although there was angiographic evidence of increased lysis, the results 
were disappointing because of unacceptably high rates of intracranial bleeding and 
worse outcomes than in the control group [Meyer, 1965]. An alternate fibrinolytic agent, 
urokinase, was subsequently tested in patients with acute stroke in 1976. In this small 
trial of 31 patients the investigators demonstrated a substantial increase in plasma 
thrombolytic activity with production of relatively minor blood coagulation defects. 
However, there were significant bleeding complications with no evidence of early clinical 
improvement [Fletcher, 1976]. It should be noted that these patients were given 
urokinase up to 36 hours after the onset of symptoms, and that haemorrhagic strokes 
were not reliably excluded with brain imaging prior to the intervention.     
 
3.1.2 Despite these early setbacks, interest in thrombolytic therapy for acute stroke re-
emerged towards the end of the 1980s. A number of open label [Brott, 1992; Haley, 
1992] and subsequently randomised placebo-controlled pilot studies [Haley, 1993; 
Yamaguchi, 1993] were performed which demonstrated potential efficacy as well as 
safety of a new generation thrombolytic agent, recombinant tissue plasminogen 
activator (tPA). This compound, called alteplase, is marketed by Genentech under the 
trade name Activase. It is a recombinant form of an endogenous human serine protease 
that acts by converting plasminogen to plasmin. Unlike streptokinase and urokinase, tPA 
is fibrin-selective and preferentially activates fibrin-bound plasminogen [Wechsler, 
2011]. 
 
3.1.3 In the first large open-label safety trial of tPA, 74 patients with acute ischaemic 
stroke were recruited from three centres in the United States (US) from 1987 to 1989. A 
dose-escalation design was used with dosing tiers allocated on the basis of complication 
rates. Exclusion criteria were ages over 80 or below 18 years, any clinical or radiological 
suggestion of intracranial or subarachnoid haemorrhage, prothrombin time (PT) > 15 
seconds, a platelet count of <100,000/mm3 or known bleeding diathesis (patients 
receiving heparin were eligible if the partial thromboplastin time [PTT] immediately 
before treatment was normal), a history of trauma or significant surgery within the 













days, lumbar puncture or arterial puncture of a noncompressible site within the previous 
7 days, a pre-treatment blood pressure >200 mm Hg systolic or >120 mm Hg diastolic, 
previous cerebral haemorrhage or ischemic infarction within 3 months, other serious 
medical illness that might interfere with the study, and inability to obtain informed 
consent. Additional exclusion criteria were added following the occurrence of major 
bleeding complications in two patients: mean arterial blood pressure >133 mm Hg, 
recent transmural myocardial infarction and pericarditis. In this study patients were 
eligible only if they demonstrated a measurable severe neurological deficit, and were 
able to receive the intervention within 90 minutes of onset. Serial clinical evaluations 
were performed during the admission, and at 3 months using the National Institutes of 
Health Stroke Scale (NIHSS), a validated [Brott, 1989] standardised neurological 
examination tool. Clinical improvement was defined as an improvement of ≥4 points on 
the NIHS scale at 24 hours after thrombolysis. Uncontrasted CT scans were performed 
routinely on presentation, at 18 to 30 hours, 7-10 days, and 3 months post-tPA.  
 
Symptomatic intracranial haemorrhage (SICH) occurred in 4% of patients, and was 
significantly related to higher doses of tPA. None of the 58 patients treated with ≤ 0.85 
mg/kg developed intracranial haematoma. Major neurological improvement occurred in 
34 patients (46%) at 24 hours from the initiation of tPA, and was not related to tPA dose 
or stroke sub-type [Brott, 1992].  
 
3.1.4 A second, smaller open label dose-escalation study of 20 patients was conducted in 
three US hospitals between 1988 and 1989. The time window for administration of tPA 
was extended to include those with symptoms of 91 to 180 minutes’ duration. This study 
again demonstrated an increased risk of intracerebral haemorrhage (ICH) with doses 
≥0.85 mg/kg, with the 2 fatal ICHs occurring in this high range. Asymptomatic 
haemorrhagic conversion of the infarction was observed on the follow-up head CT scans 
in four of the patients and was not dose related. SICH in this series was 10% overall and 
17% at the two higher dose tiers. Major clinical improvement was observed at 24 hours 
in only 15%, significantly lower than in the ≤ 90-minute cohort. This could possibly be 
attributed to worse baseline NIHSS scores. The authors concluded that further 













efficacy and safety of both the higher dose range and extended time window [Haley, 
1992].  
 
3.2 Definitive trials 
3.2.1 In response to these recommendations and in preparation for a larger more 
definitive trial, a bridging study was conducted over 1 year from 1990 to 1991 across 13 
American hospitals. Patients with acute stroke were randomised to receive either 
alteplase 0.85mg/kg or placebo within 3 hours of onset of symptoms. The primary 
endpoint tested efficacy of the intervention, and was defined as an improvement in the 
NIHSS of ≥4 points at 24 hours determined by a separate blinded evaluator. Of the 20 
patients randomised within 90 minutes, significantly more (6 out of 10 patients) 
improved in the tPA group compared to those who received placebo (1 out of 10) 
[Haley, 1993]. This clear demonstration of benefit paved the way for the pivotal National 
Institute of Neurological Disorders and Stroke Recombinant Tissue Plasminogen 
Activator (NINDS rt-PA) Stroke Study [NINDS, 1995], which in turn led to FDA approval 
for the use of intravenous tPA for acute stroke in 1996. 
 
3.2.2 Part 1 of the NINDS rt-PA trial was designed to measure the activity of tPA by testing 
whether a greater proportion of patients receiving the intervention had neurological 
improvement at 24 hours compared with those given placebo. The primary outcome 
was defined as an improvement by 4 or more points in the NIHSS score or a complete 
resolution of the neurological deficit.  
 
Part 2 assessed whether tPA provided sustained clinical benefit at 3 months; the primary 
hypothesis was that a greater proportion of patients treated with tPA compared with 
placebo would recover with minimal or no deficit 3 months after treatment. Four 
outcome measures were used: the Barthel Index which measures ability to perform 
activities of daily living; the modified Rankin score (mRS) as a global assessment of 
disability; the Glasgow Outcome Scale as a measure of overall function; and the NIHSS to 
measure neurological deficit. Favourable outcomes were defined as scores of ≤1 on the 













Patients from both parts of the trial were further divided into three strata of time to 
treatment after stroke onset: 0 to 90, 91 to 180, and 0 to 180.     
 
Eligibility criteria for inclusion were similar to those used in the open label safety study 
of 1992. The investigators considered patients for randomisation who had suffered an 
ischaemic stroke with a clearly defined time of onset, had a measurable deficit on the 
NIHSS, and had no evidence of intracranial haemorrhage on baseline CT scanning. In this 
study patients were excluded if they had a systolic blood pressure above 185 mm Hg or 
diastolic blood pressure above 110 mm Hg or if aggressive treatment was required to 
reduce their blood pressure to these limits. Other exclusion criteria were rapidly 
improving or minor symptoms or a seizure at the onset of stroke, and glucose 
concentrations below 2.7 mmol/l or above 22.2 mmol/l.  
 
Safety monitoring was performed with CT scanning at 24 hours, 7 to 10 days, and when 
haemorrhage was clinically suspected. Symptomatic intracranial haemorrhages were 
defined as any new haemorrhage detected on CT scanning accompanied by a decline in 
neurological status or preceded by a clinical suspicion of haemorrhage.  
 
A total of 624 patients underwent randomisation to receive either placebo or alteplase 
at a dose of 0.9mg/kg. Treatment groups were well matched in terms of demographic 
characteristics and baseline neurological deficit, except for age and prior aspirin use, 
which were slightly higher in the tPA group. There were minimal protocol deviations. In 
part 1 of the trial no significant difference was seen in the primary outcome between 
patients receiving tPA and those receiving placebo for any time stratum (47% and 39%, 
respectively; relative risk with tPA, 1.3; 95% CI 0.9 to 1.6; p = 0.21 for treatment 
between 0 to 180 minutes). However, for the additional 333 patients randomised to part 
2, the rate of a favourable outcome was significantly greater with intravenous (IV) tPA 
than with placebo with each of the 4 outcome measures and across all time strata at 3 
months (odds ratio, 1.7; 95% CI 1.2 to 2.6; p = 0.008). This translated into a 12% absolute 
increase in the number of patients with minimal or no disability on the Barthel index, an 
11% absolute increase in the number of patients with NIHSS scores of 0 or 1, and a 13% 













group receiving tPA. Similar benefit with tPA was seen for both secondary outcomes of 
part 1 and in the combined analysis. Importantly this greater benefit after tPA therapy as 
compared with placebo treatment was not accompanied by an increase in severe 
disability or mortality.   
 
Early SICH occurred more frequently in the tPA group (6.4% versus 0.6%; p < 0.001 for 
the combined analysis). Patients with severe deficits and cerebral oedema at baseline 
had higher rates of symptomatic intracranial bleeding, but post-hoc analysis 
demonstrated that these subgroups nevertheless derived overall benefit from tPA 
[NINDS t-PA Stroke Study Group, 1997]. The rate of asymptomatic intracerebral 
haemorrhage was similar in the two groups. The improved clinical outcome and reduced 
incidence of intracranial bleeding compared with other randomised trials of 
thrombolysis for acute ischaemic stroke was attributed to the early use and lower dose 
of tPA in this study.       
 
3.2.3 Another large randomised placebo-controlled trial of tPA for acute hemispheric 
stroke was undertaken in 75 European centres from 1992 to 1994 [Hacke, 1995]. Eligible 
patients were between the ages of 18 to 80 with moderate to severe stroke who 
presented within 6 hours of symptom onset. Patients with mild strokes defined by a 
Scandinavian Stroke Scale (SSS) > 50 were excluded. The primary endpoint was a 
difference in ADLs defined as an increase of 15 or more points on the Barthel Index, and 
the secondary endpoint measured global disability and death using the mRS, both at 3 
months.  
 
A total of 620 patients were included in the intention to treat (ITT) analysis, and 511 
were randomised to receive either tPA at 1.1mg/kg or placebo. There were no 
significant demographic differences between the two groups, as well as in stroke type 
and severity. Significant improvement in Rankin scores at 90 days for patients who 
received tPA was seen in both the ITT and target population (TP) analyses. The OR for 
being asymptomatic or independent after treatment with tPA was 1.29 (95% CI 1.09 to 
1.54) and NIHSS scores were significantly better at both 24 hours and 3 months. Mean 













revealed more deaths at 90 days in the treatment group, most of these were in patients 
with major protocol violations including major early infarct signs and concomitant 
heparin use. In the TP analysis no significant difference in the incidence of haemorrhage-
related death was found (4.2% in the tPA group and 2.7% in the placebo group, p = 
0.37), however, parenchymal haematoma was significantly more frequent in the tPA 
group, occurring in 19.8%.  The incidence of haemorrhagic transformation of the infarct 
was not statistically different in treated (42.8%) and placebo (36.8%) patients.  
 
The authors concluded that thrombolysis was effective in improving functional 
outcomes, but that this benefit did not outweigh the increased mortality rate at 3 
months. They emphasised the need for careful patient selection, specifically to exclude 
those with extended infarct signs on CT scanning in order to avoid high complication 
rates. This trial can be criticised for three reasons. Firstly, the investigators elected to 
use a higher dose of tPA even after the publication of dose-escalation studies in the USA 
(described above) which showed increased rates of significant bleeding in the patients 
randomised to >0.85mg/kg tPA. Secondly, they used a time window of up to 6 hours 
after symptom onset, again after other studies demonstrated worse outcomes beyond 
90 minutes. Finally, a significant minority (17%) of patients included in the analysis had 
protocol violations, mostly including extensive ischaemic changes on baseline CT.   
 
3.2.4 As a result of these findings a second large multi-centre European-Australasian trial, 
designated ECASS II [Hacke, 1998], was designed to assess the safety and efficacy of 
thrombolysis with alteplase at the same dose used in the NINDS study within 6 hours of 
acute stroke. Eligibility criteria were the same as for ECASS I, except that patients with 
brain swelling exceeding 33% of MCA territory were excluded. The primary endpoint was 
the proportion of patients with a favourable outcome as defined by a mRS of 0 to 1 at 3 
months. SICH was defined as bleeding at any site in the brain accompanied by any 
clinical deterioration or an increase in the NIHSS score by 4 or more points.  
 
A total of 800 patients were randomised between October 1996 and January 1998. 
There was no significant difference in baseline variables between the alteplase and 













achieved in 40.3% (95% CI 35.6 to 45.4) of patients in the alteplase group and 36.6% 
(95% CI 31.8 to 41.6) in the placebo group, giving a non-significant absolute difference of 
3.7% in favour of alteplase (p = 0.277). A post-hoc analysis showed that significantly 
more patients in the alteplase group were independent (mRS 0 to 2) compared with the 
placebo group (54.3% [49.5 – 59.1] versus 46.0% [41.1 - 50.9]; p = 0.024) at day 90. 
There was no difference in overall mortality at both 7 days and 3 months (10.3% in the 
alteplase group). Intracranial haemorrhage occurred in 48.4% and 40.2% of patients in 
the alteplase and placebo groups respectively. There was a 2.5 fold excess in 
symptomatic intracranial bleeds with alteplase, but this did not impact on overall 
morbidity or mortality.  
 
3.2.5 Lower baseline median NIHSS scores of 11, and improved early stroke care are 
possible explanations for better placebo response and lower mortality in ECASS II 
compared with ECASS I and the NINDS study. ECASS II was underpowered to define the 
optimal time interval for administration of thrombolysis and failed to show efficacy of 
thrombolytic treatment given in the 6 hour time window. However the safety data was 
consistent with those of the NINDS trial, thus supporting the use of alteplase for routine 
management of acute ischaemic stroke within 3 hours of symptom onset, and possibly 
beyond.   
 
3.3 Consolidating the evidence 
3.3.1 Subsequent large observational trials and meta-analyses have provided good 
evidence for the efficacy and safety of alteplase for treatment of acute ischaemic stroke. 
The latest Cochrane review included 26 placebo-controlled trials with a variety of 
thrombolytic agents and ranges of times from stroke onset to treatment involving 7152 
patients [Wardlaw, 2009]. Over half of the data was from trials testing tPA. They found 
that treatment within three hours of stroke significantly reduced the proportion of 
patients who were dead or dependent (mRS ≥ 3) at 3 to 6 months after stroke (OR 0.71, 
95% CI 0.52 to 0.96), with no statistically significant adverse effect on death (OR 1.13, 
95% CI 0.86 to 1.48). This overall benefit was demonstrated despite an increased risk of 
SICH which occurred in 7.7% of patients receiving thrombolysis versus 2.1% of those 













3.3.2 Intra-arterial fibrinolysis has a theoretical advantage over IV tPA because of greater 
ability to recanalise large arterial occlusions and is an emerging form of treatment in 
specialised units. A recent meta-analysis of 5 randomised controlled trials including 395 
patients with proximal vessel occlusions showed that IA thrombolysis within 6 hours of 
stroke symptom onset was associated with increased good and excellent outcomes at 90 
days according to mRS criteria (numbers needed to treat = 6.8 and 7.7, respectively). 
Similarly to IV tPA there were increased rates of symptomatic bleeding, but this did not 
result in higher mortality compared to placebo (20.5% vs 24.0%; OR 0.82; 95% CI 0.48 to 
1.39) [Lee, 2010]. IA thrombolysis with or without mechanical clot disruption or 
extraction may be an option for patients with major ischaemic stroke due to occlusion of 
middle cerebral or basilar arteries who are otherwise not candidates for IV tPA 
presenting within 6 hours of stroke onset [Bryer, 2010]. 
 
3.3.3 Bridging therapy with IV tPA followed by IA tPA has shown promise in an open label 
study with high recanalisation rates and similar clinical outcomes to the NINDS rt-PA trial 
[IMS Study Investigators, 2004], but no clinical trials have been performed to adequately 
assess this treatment modality. 
 
3.4 Use in routine practice 
3.4.1 There were concerns that similar results might not be achieved with tPA outside of 
clinical trial settings, and this has been investigated in a number of open label studies. A 
meta-analysis of 15 open-label studies including 2639 patients treated with alteplase in 
routine clinical practice was published in 2003 [Graham, 2003]. It found slightly lower 
rates of SICH 5.2% (95% CI 4.3 to 6.0) and overall ICH rates (11.5%) compared with the 
NINDS-tPA trial, with a similar number of patients (37%) achieving modified Rankin 
scores of ≤1.  
 
3.4.2 In Canada tPA therapy for acute stroke was granted a conditional licence in 1999 
pending the results of a prospective observational cohort study designed to assess the 
safety and efficacy of thrombolysis in routine clinical practice. The CASES study included 
all patients given alteplase over the period February 1999 to June 2001. The primary 













and secondary endpoints included independence (mRS 0 to 2) and complete 
neurological recovery (NIHSS score 0 to 1). SICH was defined as any decline in clinical 
neurological status associated with a new bleed detected on CT scan.  
 
Data on 1135 patients from 60 Canadian centres were collected. The cohort consisted of 
54.9% males and had a median age of 73 (IQR 63 - 80). Stroke severity was high with a 
median NIHSS score of 14 (IQR 9 - 19). The median time from stroke onset to treatment 
was 155 minutes (IQR 130 - 175). The rate of excellent outcome according to adjusted 
mRS was 36.8%, not significantly different to that reported in other series. SICH occurred 
in 4.6% (95% CI 3.4 to 6.0) and 28.9% of patients had some degree of intracranial 
bleeding. The overall 90-day mortality was 22.3% (95% CI 20.0 to 25.0). No differences in 
the rates of excellent outcome or SICH were observed in patients treated in the high-
volume and low-volume centres or between the tertiary care hospitals and the 
community hospitals. Based on the findings that tPA has similar safety and efficacy 
profiles in routine practice to clinical trials, the authors recommended widespread 
development of infrastructure to enable delivery of thrombolysis to people suffering 
acute ischaemic stroke [Hill, 2005]. 
 
3.4.3 The European Medicines Evaluation Agency allowed registration of tPA for acute 
stroke in 2002 on condition of the implementation of an observational safety study 
(SITS-MOST) and of a prospective, randomised, placebo-controlled trial of tPA 
administered between 3 and 4.5 hours after stroke onset (ECASS III).  
 
The SITS-MOST study was also designed to address concerns about the applicability of 
data from randomised controlled trials to individuals in daily clinical practice. Patients 
were recruited into this prospective open multicentre observational study from centres 
across Europe with varying degrees of experience in stroke thrombolysis. Inclusion and 
exclusion criteria were similar to those used in the NINDS trial: any patient between the 
ages of 18 and 80 with acute ischaemic stroke treated with alteplase within 3 hours of 
symptom onset with no contraindications to thrombolysis. Primary outcome measures 
were SICH (defined in the SITS-MOST protocol as local or remote parenchymal bleeds 













or death at 3 months. A secondary outcome measure was functional independence 
defined by mRS of 0 to 2. The proportion of patients with mortality, SICH (using the 
NINDS/Cochrane definition of any bleed plus any neurological deterioration or death 
within 7 days) and independence were compared with pooled results from randomised 
trials.  
 
6483 patients from 285 centres were included between the years 2002 and 2006. 
Baseline and demographic data, as well as stroke severity were similar for the SITS-
MOST cohort and patients from the other trials. The median age was 68 years and the 
median NIHSS score was 12.   
 
The proportion of patients with SICH according to NINDS criteria as 7.3% (95% CI 6.7 to 
7.9) compared with 8.6% (95% CI 6.3 to 11.6) in the pooled data. The number of SICH as 
defined by the stricter SITS-MOST protocol was 1.7% (107/6444; 95% CI 1.4 to 2.0), and 
rose to 4.6% (296/6442; 95% CI 4.1 to 5.1) when using the ECASS criteria (described in 
section 3.2.4). The number of patients with any intracerebral haemorrhage was 
approximately 17.3%. Mortality at 3 months was 11.3% (95% CI 10.5 to 12.1), and 54.8% 
(95% CI 53.5 to 56.0) of patients were independent (mRS 0 – 2), both better outcomes 
than in controlled trials. Complete recovery at 3 months was seen in 38.9% (95% CI 37.7 
to 40.1) of patients in SITS-MOST compared with 42.3% (95% CI 37.8 to 47.0) in 
randomised controlled trials. At the time of discharge the median NIHSS score had fallen 
to 4 (IQR 1 - 11). There were no significant differences in the rates of complete recovery 
or SICH between experienced and new centres. The results of this study confirmed that 
alteplase is an effective treatment if administered within 3 hours of stroke onset and has 
a similar safety profile to that in randomised controlled trials when used in routine 
clinical practice [Wahlgren, 2007].  
 
3.5 Optimal time window 
3.5.1 The efficacy of thrombolytic therapy has a clear inverse association with the interval 













NINDS study data showed a significant improvement of outcomes at both 24 hours and 
at 3 months in the group given alteplase between 0 and 90 minutes of stroke onset-to-
treatment (OTT) compared with those thrombolysed at 91 to 180 minutes. The adjusted 
odds ratio for a favourable outcome at 3 months was 2.11 (1.33 - 3.35) in the 0 to 90 
minute stratum and 1.69 (1.09 - 2.62) in the 91 to 180 minute stratum, a significant OTT-
treatment interaction. For improvement at 24 hours, the odds ratios were 1.71 (95% CI 
1.09 to 2.70) and 1.12 (95% CI 0.71 to 1.76, p 5 0.62) for the earlier and later OTT groups 
respectively. There was no effect of OTT on the occurrence of ICH [Marler, 2000].  
 
3.5.2 Similar findings were demonstrated in a pooled analysis of 2775 patients from 6 
randomised trials of tPA given over a range of OTTs from 3 to 6 hours. The median age 
was 68 years (IQR 60 - 74) with median baseline NIHSS scores of 11. Compared with 
controls, the hazard ratios for death at 3 months in those treated with tPA were not 
significant over OTT periods up until 270 minutes, but exceeded 1 (1.45 [1.02–2.07]) in 
patients treated later. Although substantial intracerebral haemorrhages were seen more 
frequently in the tPA group (5.9% versus 1.1% p < 0.0001) and in older patients (median 
age 72, IQR 65 - 76), they were not associated with OTT (p = 0.71). In terms of outcomes, 
the benefit from treatment increased as OTT decreased: the odds ratio of a favourable 
outcome for patients treated with tPA compared with controls was 2.81 (1.75 – 4.50) for 
those treated within 90 min and 1.55 (1.12 – 2.15) for those treated within 91–180 min. 
This benefit was shown to extend beyond 3 hours with demonstration of an odds ratio 
of 1.40 (95% CI 1.05 to 1.85) for favourable outcome for those treated within 181 – 270 
minutes [Hacke, 2004].  
 
3.5.3 This evidence, together with a request by the European Medicines Agency, led to 
ECASS III, a randomised placebo-controlled trial designed to test the efficacy and safety 
of alteplase administered between 3 and 4.5 hours after the onset of acute ischaemic 
stroke.  
 
In this study 821 patients from 130 European sites were randomised between July 2003 
and November 2007 to receive either alteplase 0.9mg/kg or placebo between 3 and 4.5 













characteristics except for initial stroke severity (worse in the placebo group, median 
NIHSS scores 9 versus 10 in the treatment group) and history of prior stroke. The 
primary efficacy endpoint was disability at 3 months, assessed as favourable with mRS 0 
to 1 and as unfavourable with scores from 2 to 6. A secondary endpoint included mRS 
scores dichotomised as 0 to 2 and 3 to 6.  Safety endpoints included overall mortality at 
90 days, any intracranial haemorrhage and SICH defined as bleeds identified as the 
predominant cause of neurological deterioration leading to an increase in 4 or more 
points on the NIHSS scale or death.  
 
Compared with placebo, significantly more patients in the tPA group achieved a 
favourable outcome (52.4% versus 45.2%; OR 1.34 (1.02 - 1.76), p = 0.04). This 
represented an absolute improvement of 7.2%, and translates into 1 patient having a 
favourable outcome for every 14 patients treated in the extended time window. The 
benefit was maintained after adjustment for confounding baseline variables (odds ratio, 
1.42; 95% CI 1.02 to 1.98; p = 0.04). Despite the significantly higher rates of total (27.0% 
vs. 17.6%; OR 1.73 (1.24 - 2.42) p = 0.001) and symptomatic intracranial bleeding (2.4% 
vs. 0.2%; OR 9.85 (1.26 - 77.32) p = 0.008) in the patients who received thrombolysis, 
there was no difference in 3 month mortality between the two groups: 7.7% versus 8.4% 
for placebo; OR 0.90 (0.54- 1.49), p = 0.68.   
 
The authors noted that although alteplase was associated with significant improvement 
in clinical outcome when administered between 3 and 4.5 hours after the onset of 
stroke symptoms, this benefit can be maximised by receiving treatment as early as 
possible as demonstrated by the results of the pooled analysis [Hacke, 2008]. 
 
3.5.4 An updated pooled analysis incorporating data from 8 trials (including ECASS III) with 
3670 patients was published in 2010 and confirmed that benefit is seen with tPA up to 
4.5 hours after onset of stroke symptoms. The confidence intervals for favourable 
outcomes, defined both by mRS less than 1 and a composite endpoint of global function 
test scores, crossed the no-effect line at 270 minutes from OTT. There was no 
interaction of large intracranial bleeds with OTT, although predictably more, 4.2% (OR 













Despite this, the analysis found a significant increase in mortality with alteplase (OR 1.49 
(1.00 to 2.21), p = 0.0501) only after a delay of approximately 4.5 hours. In their 
discussion the authors noted that “the effectiveness of thrombolysis is beyond dispute” 
but that there is evidence of significant harm with treatment beyond 270 minutes, 
reinforcing the message that alteplase is more effective when given sooner [Lees, 2010].      
 
3.5.5 In summary, there is good evidence from both randomised, placebo-controlled trials 
and real-world observational open-label studies that tPA is an effective treatment for 
acute ischaemic stroke. When given alteplase at 0.9mg/kg within 3 hours of stroke 
symptom onset, patients are more than 30% more likely to have minimal or no disability 
at 3 months, resulting in a 12% absolute increase in the number of patients with mRS 
below 1. The benefit to the community would be an additional 120 independent 
survivors per 1000 patients treated. This benefit is maintained when used in routine 
clinical practice, even at inexperienced centres. Alteplase is efficacious up to 4.5 hours 
after symptom onset with an odds ratio of 1.34 for near complete recovery. Early is 
treatment is essential, however; the number needed to treat (NNT) increases as the gap 
between symptom onset and thrombolysis widens. At a time window of 0 to 90 minutes, 
the NNT is approximately 5, but at 181 to 270 minutes 15 patients need to be 
thrombolysed to achieve 1 additional excellent outcome attributable to treatment. The 
increased risk of symptomatic intracranial haemorrhage is substantial, but is not 
affected by later treatment and does not come at a cost of increased mortality or 
disability: “tissue plasminogen activator has no net risk for acute stroke therapy” 
[Bambauer, 2006].   As a result of the above evidence, the South African Stroke Society 
endorsed thrombolysis with tPA within 4.5 hours of symptom onset as standard of care 
for acute ischaemic stroke in facilities able to provide this type of treatment according to 
the stipulated recommendations [Bryer, 2010].  
 
3.6 Thrombolysis delivery 
3.6.1 Tissue plasminogen activator represents a significant therapeutic breakthrough in 
the treatment of stroke. However, its impact on the general population has been 
limited. This is mainly due to the narrow time window allowed for administration but 













estimated that only 1.4% of 90200 patients with ischemic stroke received thrombolysis 
over the 2.5-year study period [Hill, 2005]. It has been calculated that between 1.8 to 
3.0% of all ischaemic stroke patients are treated with tPA in the United States [Qureshi, 
2005; Kleindorfer, 2008]. In an analysis of 495186 ischemic stroke admissions in the USA 
between the years 2005 and 2007, only 2.4% received tPA. There was a wide range (0% 
to 23%) of individual hospital-reported treatment rates: 64.2% reported no treatments 
with tPA for ischemic stroke, 18.8% reported tPA rates between 0 and 2.4%, 16.0% 
reported tPA rates between 2.4 and 10%, and only 0.9% reported 10% treatment rates. 
The most important factor for an association with treatment rates was bed numbers, 
with smaller hospitals providing less thrombolysis, but rural designation and population 
density were also significant. An estimated 40% of the US population was served by 
hospitals thrombolysing less than 2.4% of their patients [Kleindorfer, 2009].   
 
3.6.2 A retrospective population-based study of 1.3 million people in the greater 
Cincinnati area was conducted between 1993 and 1994 to identify factors affecting the 
eligibility of stroke patients for tPA. Of the 2308 patients with ischaemic infarcts, only 
39% had documentation of exact stroke times. Less than a quarter (22%) of all patients 
presented to an emergency department within 3 hours of stroke onset; 19% presented 
in less than 2 hours. Half of the patients arriving before 3 hours were ineligible for tPA 
on the basis of mild stroke severity, medical and surgical history, or blood tests. On the 
basis of this data, the authors estimated that only approximately 8% of ischaemic stroke 
patients presenting to an ED were eligible for tPA [Kleindorfer, 2004]. 
 
3.6.3 Over the years 1996 to 1999, 2165 patients presenting to a Canadian teaching 
hospital with acute stroke were prospectively studied to identify barriers to receiving 
tPA. Almost three quarters (73.1%) of those diagnosed with ischaemic strokes were 
excluded because of delay in presentation to the emergency department beyond 3 
hours. Reasons for delay included uncertain time of onset (24.2%), patients waiting to 
see if symptoms would improve (29%), transfer from an outlying hospital (8.9%), and 
inaccessibility of treating hospital (5.7%). Of those patients arriving within 3 hours of 
symptom onset, only 26.7% received thrombolysis. The most common reason for 













patients remained dependent at hospital discharge or died during hospital admission. It 
was estimated that only 4.7% of ischaemic stroke patients admitted in the region over 
the study period received tPA [Barber, 2001].  
 
3.6.4 A systematic review analysed 54 studies over the years 1990 to 2001 that assessed 
barriers to delivery of thrombolysis for acute stroke [Kwan, 2004]. In European hospitals 
the proportion of patients arriving within 3 hours of stroke onset ranged from 25 to 
61%, in the USA/Canada 30 to 56%, and in Asia 24 to 50%. Delay to treatment over 3 
hours or unknown onset time was the commonest reason (up to 94%) for tPA 
ineligibility. The most consistent pre-hospital barrier was the patient’s or family’s poor 
knowledge of stroke symptoms. Lack of knowledge of the risks and benefits of 
thrombolysis may have led to a refusal to consent in up to 10%. Another barrier 
identified was initial presentation to a GP rather than the emergency department. Other 
US reviews also identified lack of public knowledge of stroke symptoms and tendency 
not to seek immediate care as major factors in treatment delay [Bambauer, 2006]. 
 
3.6.5 A prospective study of all patients diagnosed with acute ischaemic stroke across 11 
hospitals in California showed that the overall rate of thrombolytic treatment would 
have increased from 4.3 to 28.6% if patients had called emergency services immediately 
after symptom onset. The authors estimated that 57% could have been treated if all 
patients with known time of symptom onset had presented within 1 hour and had 
received optimal care [CASPR Investigators, 2005].  
 
3.6.6 Centres that have implemented acute stroke response systems have demonstrated 
improved rates of thrombolysis delivery. A Canadian study showed that a pre-hospital 
triage initiative resulted in a doubling of the number of stroke patients arriving within 
2.5 hours at a regional hospital with thrombolysis capabilities. Their protocol included 
identification of acute stroke by paramedics allowing for direct routing to a thrombolysis 
centre and pre-hospital notification of an on-call stroke team. Compared with a four-
month period before the implementation of the protocol, the tPA treatment rate 














3.6.7 These findings have been supported by a recent publication from a stroke centre in 
Paris [Dalloz, 2012]. After the implementation of a pre-notification system, 59.6% of 213 
confirmed hyperacute ischaemic strokes received thrombolysis. A systematic review 
performed by the same authors showed that door-to-needle time was shorter and rates 
of thrombolysis were significantly higher (mean 54.7% among 609 patients) in hospitals 
that used a pre-notification stroke code compared with those that did not (mean 18.2% 
among 297 patients). An integrated acute stroke referral network has also been 
successfully piloted in a developing country as described below in section 4.1.10 
[Muengtaweepongsa, 2010]. 
 
3.6.8 Fear of emergency physicians about the increased risk of intracerebral bleeds and 
perceived lack of efficacy with tPA is another obstacle limiting its use. A survey found 
that 40% of emergency department physicians would not use alteplase for acute stroke, 
with 65% citing risk of intracerebral haemorrhage as the reason for not using tPA, and 
23% of physicians citing perceived lack of benefit [Brown, 2005]. This view has also been 
expressed in South Africa [Lahri, 2011].  
 
3.7 Cost 
3.7.1 Some authors in the US feel that inadequate funding may be the greatest obstacle to 
the use of tPA in acute stroke management. Physician reimbursement rates have not 
been in line with the substantially increased expense of administering tPA in hospital. In 
a comparison of hospital expenses for over 110000 stroke in-patients in California 
between 1998 and 2000, the average cost for those treated with tPA was almost $18000 
greater than for those who were not. This may reflect the higher baseline stroke severity 
amongst patients who are thrombolysed, as well as the more intensive care and 
investigations they receive [Bambauer, 2006].    
 
3.7.2 Despite the increased early expense, tPA has been shown to be both a cost-effective 
and even a cost-saving treatment. In the NINDS trial, the average length of stay was 
significantly shorter in tPA-treated patients than in placebo-treated patients (10.9 versus 
12.4 days; p = 0.02) and more tPA patients were discharged to home than to inpatient 













every 1000 patients treated with tPA, there would be an additional 55 intracranial 
haemorrhages but 116 more patients would be discharged home compared with 
placebo. A cost analysis predicted a 1 year cost savings of about $600000 per patient 
receiving tPA. This is due to reduction in nursing home and rehabilitation requirements 
[Fagan, 1998]. An economic analysis for the National Health Service in the United 
Kingdom suggested cost-effectiveness or cost savings with tPA use in ischaemic stroke, 
particularly for longer term health outcomes. This study estimated a 78% probability of a 
gain in quality-adjusted survival during the first year, even including data of patients 
treated up to 6 hours after stroke [Sandercock, 2004].    
 
4. THROMBOLYSIS IN DEVELOPING COUNTRIES 
4.1 Delivery 
4.1.1 There are few reports on the use of tPA for ischaemic stroke in developing countries. 
A search of Medline does not reveal any publications on thrombolysis for stroke in 
Africa. This treatment option is only available in a minority of developing countries 
including Brazil, Argentina, Senegal, Iran, Pakistan, China, Thailand, and India; and even 
in the places where it is offered, the number of patients receiving alteplase for stroke is 
very low [Durai Pandian, 2007]. 
 
4.1.2 The Argentinean National Stroke Registry (ReNACer) collected data from 1991 
patients with acute ischaemic stroke from 74 medical facilities offering various levels of 
care. Only 5.7% of all patients were admitted to stroke units, and a total of 21 (1.05%) 
patients received thrombolysis over a 2-year period from 2004 [Sposato, 2008].  
 
4.1.3 Over the years 2001 to 2004, only 2.1% of 1624 acute stroke patients presenting to 
an urban referral hospital in Bangkok received thrombolysis [Suwanwela, 2006].  
 
4.1.4 In an Indian cohort, 54 out of 1096 patients (≈5%) with acute stroke were 
thrombolysed over four years at a tertiary hospital in Delhi. The most common reason 
for ineligibility was arrival at hospital outside of the treatment window (38%). Over a 
quarter of otherwise eligible patients did not receive tPA because of inability to afford 














4.1.5 The first report of thrombolysis outcomes in Pakistan demonstrated even lower 
rates of tPA utilisation. From 2005 to 2007 only 18 out of 1185 (1.5%) stroke patients at 
Aga Khan Hospital were thrombolysed, while at Liaquat National Hospital the rate was 3 
out of 575 (0.52%) stroke patients over 1 year in 2007. The authors identified factors 
contributing to the low rates of thrombolysis in Pakistan. These included limited centres 
with CT scanners, an unreliable supply of on-site tPA, poor public awareness of stroke 
symptoms, and financial constraints in a fee-for-service health care system where the 
cost of tPA is higher than the per capita annual income [Wasay, 2010].  
 
4.1.6 Another study from India reported that of 64 rural patients screened for 
thrombolytic therapy, 31% reached hospital within 3 hours and 16% were eligible to 
receive tPA, but none received the intervention. The main reasons for this included the 
high cost of alteplase and inability of poor patients to afford it, the lack of 24 hour 
emergency CT scanning, dependence on the public transport system to get to hospital, 
and a low level of awareness of the importance of time in acute stroke management 
[Nandigam, 2003].  
 
4.1.7 A hospital in the low income and densely populated Indian region of Uttar Pradesh 
was able to thrombolyse 32 of 584 patients (≈5%) with acute stroke over a 3-year period 
from September 2004. The most common reason for disqualification from tPA therapy 
was arrival outside of the 3 hour window period, occurring in 48%. Of those who would 
have otherwise been eligible, 40% could not afford tPA [Sharma, 2008].  
 
4.1.8 At a single centre in Ho Chi Min City, Vietnam, only 121 out of 6171 patients (2.1%) 
with acute ischaemic stroke were thrombolysed over a 3-year period from 2006. The 
majority were ineligible because of late presentation to hospital: only 8.7% arrived 
within 3 hours of symptom onset [Nguyen, 2010].  
 
4.1.9 At a referral hospital in Punjab, India, 72 out of 489 (14.7%) stroke patients 













actually received the drug, the remainder being unable to afford the high cost of 
alteplase [Pandian, 2005].  
 
4.1.10 In the face of these challenges shared by most developing countries, a community-
based Thai hospital demonstrated improved rates of thrombolysis after the 
implementation of an integrated acute stroke referral network. The network covered 25 
rural (10- to 60-bed) hospitals, 2 regional (120-bed) hospitals, and 2 provincial (500-bed) 
hospitals, all located within 80 km of the referral centre. After arrival at their local 
hospital, usually by private transport, patients were immediately screened by trained 
clerks and nurses using a modified Cincinnati prehospital stroke tool. If acute stroke with 
onset less than 3 hours was suspected, the stroke fast track was activated whereby 
patients were immediately sent to the emergency department for baseline 
investigations, insertion of IV lines and urgent transfer arranged to the referral centre 
for CT scanning and assessment for thrombolysis. Over a 16-month period from October 
2007, 458 patients were admitted with acute ischaemic stroke. A high proportion (21%) 
received IV tPA, and of these 100 patients, 59 had been transferred from a hospital in 
the acute stroke referral network. A total of 41% of the referred patients were 
thrombolysed, and the mean OTT was 160 minutes (range 60 to 270 minutes). These 
data indicate that integration of an acute stroke referral network into a protocol of IV 
thrombolysis for acute stroke is feasible in a developing country, and helps to increase 
the rate of tPA use [Muengtaweepongsa, 2010].   
 
4.2 Efficacy and safety 
4.2.1 A number of observational studies have shown comparable efficacy and safety of 
thrombolysis when used in developing countries. The patients from the Uttar Pradesh 
study, described in section 4.1.7, had a mean age of 66 years with a mean baseline 
NIHSS score of 14 (range 8 to 22). The mean door to needle time was around 30 
minutes, well within the recommended period of less than an hour. At 48 hours 65.6% 
had improved their NIHSS score by 4 or more points. There was only 1 SICH and 1 death 
unrelated to treatment. At one-month follow-up a favourable Barthel index score of 75 














4.2.2 The larger study from New Delhi of 54 patients with comparable baseline 
characteristics showed similar positive results. None of these patients suffered SICH and 
there were no mortalities at discharge; 65% had significantly improved NIHSS scores by 
48 hours. Of note, the mean door to injection time was only 26.8 minutes (range 25 to 
67) [Padma, 2007].  
 
4.2.3 The safety outcomes of 21 patients thrombolysed at two tertiary hospitals in Karachi 
were less reassuring. In this group the mean age was 62 (range 27 to 77) years, the 
mean time delay from stroke onset to tPA infusion was 169 minutes (range 95 to 200), 
but stroke severity was not reported. A total of 4 patients (19%) died, 3 of a fatal 
intracranial haemorrhage. There were protocol violations for all patients who had 
complications [Wasay, 2010]. The small numbers and retrospective design were major 
limitations, and the findings of this study should be interpreted in this context. 
 
4.2.4 The largest published cohort of stroke patients receiving tPA in Asia is from three 
referral hospitals in Ho Chi Min City, Vietnam. Prospective data was collected on 121 
patients over the period 2006 to 2009. Just over 40% of the patients could not afford a 
second ampoule of alteplase and were treated with a lower dose (mean 0.62mg/kg). The 
mean age and NIHSS scores were 57 years and 12, respectively. In the lower dose group 
56.3% had achieved functional independence (mRS 0 to 1) by 3 months, the proportion 
in the standard dose group was 34.2%. The rate of SICH was higher in the standard dose 
group at 5.5% versus 2.1% in those receiving lower dose tPA. There were a total of 10 
deaths in the cohort (8.3%), only 2 (1.7%) resulting from bleeding complications 
[Nguyen, 2010]. 
 
4.2.5 The results of two prospective studies of tPA in Thailand showed comparable results 
to published trials from developed countries. The first reported 34 cases of severe stroke 
(median NIHSS score 20) thrombolysed over the period 2001 to 2004. Significant 
neurological improvement was achieved by 70.6%, with only 2 cases (5.9%) having 
symptomatic intracranial bleeds resulting in 1 death [Suwanwela, 2006]. The other Thai 













had achieved excellent recovery (mRS 0-1) with a mortality rate of 14%. Only 2% of 
patients suffered SICH [Muengtaweepongsa, 2010].       
 
4.2.6 In summary, thrombolysis for acute ischaemic stroke is offered in very few 
developing countries. In the places where it is available, the rates of delivery are low, 
ranging from 1 to 5%. The two main reasons for this appear to be difficulty in arriving at 
hospital within the treatment window period and the high cost of alteplase. A study did 
show, however, that integration of an acute stroke referral network in developing 
countries might help to increase the number of patients receiving thrombolysis. Despite 
concerns about efficacy and safety of tPA for routine use in developing countries, results 
from a number of observational studies of a variety of patient populations showed 
comparable favourable outcomes and complication rates to landmark trials performed 
in Western environments.    
 
5. Rationale for the study 
5.1.1 As sub-Saharan Africa progresses through a health transition the incidence of 
cerebrovascular disease is expected to rise. Currently there is evidence of similar 
prevalence rates to high-income countries, although the burden of mortality and 
disability from stroke is much higher in poorer regions. This emerging epidemic of non-
communicable disease places increasing demands on an already strained economy and 
health service. The establishment of organised stroke units has been shown to improve 
outcomes in acute stroke care for all categories of patients, and is a promising 
intervention for low-and-middle-income countries.  
 
Thrombolysis with tissue plasminogen activator is the only specific therapy for acute 
ischaemic stroke. The efficacy and safety of this intervention has been demonstrated in 
over 4000 patients in controlled trials, and continues to show reproducible benefit in 
large open-label studies on different continents. The proportion of patients receiving 
thrombolysis who achieve significant neurological improvement at discharge and 
excellent functional outcomes at 3 months is greater than those treated with placebo. 
Although this comes at a cost of increased rates of intracranial haemorrhage, there is no 













There are a number of barriers to the implementation of this effective intervention, 
limiting its use in most clinical settings to around 2% of patients with acute stroke. In 
order to maximise benefit and reduce complications, tPA needs to be administered 
within 4.5 hours from onset of stroke symptoms. This narrow window of opportunity 
represents the largest obstacle to more widespread use because of inefficient public 
transport systems and low levels of awareness about stroke. Another important barrier 
is the high cost of the drug and inability of patients in poorer countries to afford it.  
 
Despite early concern that thrombolysis may not be a viable option for treating stroke in 
developing countries, there is growing evidence of its comparable efficacy and safety 
when used in these settings. The introduction of an acute stroke support network in 
Thailand demonstrated that increased rates of tPA use is feasible and efficacious in a 
poorly resourced region. There are no published data on thrombolysis for acute 
ischaemic stroke in Africa. We therefore set out to investigate whether tPA can be safely 
used in routine practice at a tertiary stroke referral centre in South Africa, and if this 
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Stroke is an important cause of death and disability in sub-Saharan Africa, where it 
was estimated that 355 000 stroke deaths occurred in 2001,1 with a similar age-
specific prevalence to developed countries,2 but resulting in much higher levels of 
disability.3 Cerebrovascular disease is a growing problem in South Africa,4 and places 
a heavy burden on family carers in poor socioeconomic environments.5  
 
Thrombolysis with recombinant tissue plasminogen activator (tPA, alteplase) is the 
only effective specific treatment for acute ischaemic stroke. The landmark National 
Institute of Neurological Disorders and Stroke (NINDS) rt-PA trial6 in the USA in 1995 
demonstrated that patients receiving this intervention were 30% more likely to 
survive with minimal disability resulting in a 12% absolute increase in the proportion 
having excellent functional outcomes at 3 months. The benefits of thrombolysis have 
been consistently reproduced when used in routine clinical practice across different 
patient populations.7-9 Although its use increases rates of intracranial haemorrhage, 
thrombolysis has no impact on overall mortality.10  
 
Net benefit can be achieved if tPA is administered within 4.5 hours of onset of stroke 
symptoms.11 This narrow window of opportunity represents the largest obstacle to 
more widespread use because of inefficient public transport systems and low levels 
of awareness about stroke.12 This and other issues, such as cost and the availability 
of resources required to administer this treatment, have caused concerns that 
thrombolysis may not be a viable option for treating stroke in developing countries. 
However, there is growing evidence of of its comparable efficacy and safety when 
used in these settings.13-17  
 
The new South African national stroke guidelines recommend tPA as treatment for 
acute ischaemic stroke within 4.5 hours of symptom onset.18 However, there are no 
published data on the use of thrombolysis in Africa. We aimed to evaluate the early 













2. METHODS  
This was a prospective, open, observational study of all patients receiving tPA for 
acute ischaemic stroke at Groote Schuur Hospital (GSH) from January 2000 to 
February 2011. The hospital has a comprehensive stroke unit as defined by the 
national stroke guidelines.  
 
Patient eligibility was defined by the Stroke Unit protocol and included patients with 
a clinical diagnosis of acute stroke in whom it was ascertained that the time of onset 
of stroke symptoms was within 3 hours of receiving thrombolysis. After publication 
of the ECASS III trial19 in 2008 this time window was extended to 4.5 hours. Exclusion 
criteria were based on the NINDS rt-PA trial6 protocol (in our study the upper age 
limit was 75 years), which broadly restricts eligibility to those without evidence of 
intracranial blood on baseline computed tomography (CT) scanning, low risk of 
bleeding, and those without rapidly resolving symptoms or severe neurological 
deficit (National Institutes of Health stroke scale (NIHSS) >25).  
 
Baseline and demographic characteristics, stroke type and severity, time intervals, 
risk factors, and medication history were recorded. Neurological impairment and 
functional disability were assessed on arrival and at discharge using the NIHSS score 
and the modified Rankin scale (mRS), respectively. CT scans were performed at 
baseline and within 36 hours of thrombolysis, or on evidence of clinical 
deterioration.  
 
The primary outcome measure was the proportion of patients achieving significant 
early neurological recovery defined as an improvement of 4 or more points on the 
NIHSS score at discharge. The safety endpoint was the rate of symptomatic 
intracranial haemorrhage (SICH) and death. SICH was defined according to the NINDS 
rt-PA/Cochrane criteria6,20 as any new evidence of intracranial blood on CT or 
magnetic resonance imaging (MRI) accompanied by a neurological deterioration of 4 
or more points on the NIHSS score from baseline. Functional independence (i.e. an 
mRS score of 0 - 2) or an improvement of two or more points on the mRS achieved at 













The proportion of patients with SICH, mortality, independence, and neurological 
improvement were calculated and compared with the corresponding proportions in 
the alteplase arm of the NINDS rt-PA and ECASS III trials, and with observational 
studies in developed and other developing countries.  
 
Demographic profiles were compared with a cohort of unmatched patients who 
suffered ischaemic strokes but who were managed conservatively in our stroke unit. 
The latter patients were ineligible for thrombolysis, and their data were recorded in 
the same register as those who received tPA from January 2000 to April 2006.  
 
Written informed consent was obtained either from the patients or from a close 
family member. Alteplase was administered in consultation ith the attending 
neurologist or stroke physician. An intravenous (IV) dose of alteplase (0.9 mg/kg, 
with 10% given as a bolus followed by an infusion over 1 hour) was administered in 
the emergency department after the baseline CT scan was reviewed. Selected 
patients received intra-arterial (IA) alteplase.  
 
This study was approved by the UCT-GSH Human Research Ethics Committee (Ref: 
386/2011).  
 
3. RESULTS  
Forty-two patients were thrombolysed at GSH from January 2000 to February 2011. 
Their mean age was 60 (SD 12.26, range 24 - 79) and the median baseline NIHSS 
score was 14 (interquartile range (IQR) 10.5 - 17). Approximately 60% were clinically 
assessed to have large-vessel atheroembolic aetiologies. Thirty-six (85.7%) received 
IV tPA, 4 (9.5%) received IA tPA and 2 (4.8%) received bridging treatment with IV tPA 
followed by an endovascular procedure including IA tPA. Three (7.1%) patients were 
over the age of 75 years.  
 
Table 1 shows clinical data, including stroke type and severity. NIHSS data were 













patients. The mean time to tPA infusion was 160 minutes (SD 50, range 60 - 270). 
Most patients (29, 72.5%) were thrombolysed within 180 minutes. Median duration 
of hospital stay was 12 days (IQR 8 - 15.8). Table 2 compares demographic data of 
the patients receiving tPA, and unmatched patients with acute ischaemic stroke 
managed conservatively in the same unit. Of the patients who received 
thrombolysis, 25/42 (59.5%) arrived at hospital using their own transport; the next 
most common referral source was from private hospitals (5/42, 11.9%) (Fig.1).  
 
Fig. 2 illustrates early neurological outcomes grouped by severity. The median NIHSS 
score fell to 7.5 (IQR 1 - 15) by the time of discharge. Forty-eight per cent of patients 
scored in the mild range (0 - 7), compared with only 5% on arrival. At discharge 18 
(42.9%) patients had improved their mRS by 2 or more points and 17 (40.5%) were 
functionally independent. Over half (53.8%) of our patients were discharged home. 
Fig. 3 compares the proportion of patients who achieved significant neurological 
improvement in this study with that of other studies.  
 
Fig. 4 compares our patients and results from other studies for SICH (using the 
NINDS rt-PA/Cochrane definition) and mortality. Only 2 (4.8%) of our patients 
suffered SICH. Adverse effects were not significantly related to time of tPA infusion, 
age or stroke severity. All three patients aged >75 years experienced bleeding 
complications with one, aged 76, suffering a symptomatic intracranial haemorrhage 
(NIHSS 8). Another, aged 79, had an asymptomatic intracranial haemorrhage (NIHSS 
28), and the third patient, aged 78, developed a femoral haematoma (NIHSS 19).  
 
At the time of discharge a total of 3 (7.1%) patients had died, all of whom had 
admission Rankin scores of 5. Besides the single patient with fatal intracranial 
haemorrhage the deaths were unrelated to treatment; one patient died of an acute 
myocardial infarction, and the other from an additional cerebral infarct and 















4. DISCUSSION  
Two-thirds of our patients achieved significant neurological improvement after 
receiving tPA, which compares favourably with the NINDS rt-PA trial.6 Smaller 
studies from other developing countries reported similar results.13-17 The European 
Medicines Evaluation Agency allowed registration of tPA for acute stroke in 2002, on 
condition that an observational safety study be performed to address concerns 
about the applicability of data from randomised controlled trials to individuals in 
daily clinical practice. At 3-month follow-up, 54.8% of patients in this SITS-MOST 
cohort were functionally independent,7 compared with 40.5% at the time of 
discharge in our study. Although other studies demonstrated sustained clinical 
benefit of thrombolysis,20 this could not be assessed with our study design which 
was limited by a short follow-up period. However, the functional outcomes of our 
patients may be comparable with those of the SITS-MOST study as improvement 
after tPA typically occurs early because of vessel recanalisation, and further recovery 
would be anticipated in our surviving patients with rehabilitation in the 90 days post 
discharge.  
 
Our patients had a lower rate of SICH compared with the NINDS rt-PA trial (4.8% v. 
6.4%)6 and the large open-label SITS-ISTR study (8.0% for patients treated between 3 
and 4.5 hours and 7.3% for patients treated within 3 hours).9 Pooled data from five 
observational studies from developing countries show a lower proportion of patients 
suffering SICH, 9/293 (3.1%), but the rates ranged from 0 to 5.9% between the 
different centres.13-17 Although the number is small and does not represent a 
significant association, all three of our patients over the age of 75 had bleeding 
complications. Studies in the developed world support the safety of tPA in patients 
over 80 years.21 However, more caution may be needed in our setting when 
thrombolysing elderly patients.  
 
Our in-patient mortality was similar to that of the NINDS rt-PA trial (7.4%), but could 
not be compared with large observational studies such as SITS-MOST and CASES as 
these only reported 3-month mortality rates. The 7-day mortality of 11 621 patients 













the rate for those treated between 3 and 4.5 hours in the same registry was 
7.5%.9 In 3 studies from developing countries the mortality at discharge ranged from 
0 to 5.9%.13,14,16  
 
It is estimated that <2% of patients with ischaemic stroke in our hospital drainage 
area received thrombolysis, which seems comparable with data from other 
developing countries.15,16 However, our reported thrombolysis rate is an 
overestimation for the general population, as most patients with acute stroke are 
managed conservatively at lower level facilities where thrombolysis is not available.  
 
This study was not designed to identify barriers to accessing thrombolysis, but 
inferences may be drawn from our findings in this regard. Most patients who 
qualified for tPA used their own transport to hospital, suggesting that delays in the 
emergency medical services transport system may be a cause for arrival outside of 
the 4.5 hour window period. A greater proportion of patients who received 
thrombolysis were employed, and lived in brick houses compared with 
conservatively managed patients, suggesting that those with higher incomes are 
more likely to arrive at hospital within the narrow time window required for this 
intervention. As in other studies,10,12 low levels of public awareness of stroke may be 
another barrier to thrombolysis in our setting as reflected by the difference in 
education levels between the patient groups. Certain quarters in South Africa’s 
emergency medicine community22 and elsewhere are reluctant to use tPA for 
stroke,23 and this may also have contributed to the small numbers of patients 
referred from secondary level hospitals.  
 
A study limitation is the relatively small number of patients with ischaemic stroke in 
the GSH cohort that received tPA. Nevertheless, the data indicate that the use of 
thrombolysis in routine clinical practice in a South African setting has similar safety 
and early efficacy outcomes to developed and other developing countries. 
Thrombolysis is specialised and is not available to most South Africans. However, its 
benefits for reducing disability for stroke victims should be promoted in the lay and 













emergency services must be considered to facilitate early arrival and assessment at a 
designated stroke centre where thrombolysis is available. 
 
5. FIGURES AND TABLES 
Table 1: Baseline clinical characteristics of patients receiving tPA (n = 42) 
 Variable  
Age 62 (52 - 67.5) 
Male sex 54.8% 
Married 24 (57.1%) 
Systolic blood pressure (mmHg) 149 (134 - 170) 
Diastolic blood pressure (mmHg) 84 (76 - 90) 
Degree of neurological severity (NIHSS) 14 (10.5 - 17) 
 - Mild 0 - 7 2 (4.8%) 
 - Moderate (8 - 14) 19 (45.2%) 
 - Severe (≥ 15) 18 (42.9%) 
Cause of stroke   
 - Large vessel atheroembolic 25 (59.5%) 
 - Lacunar 3 (7.1%) 
 - Cardioembolic 9 (21.4%) 
 - Other 3 (7.1%) 
 - Unknown 2 (4.8%) 
Stroke onset to treatment time (min) 160 (±50) 
Data are median (IQR), mean (SD), or n (%) 
 
 
Table 2: Demographic characteristics of patients receiving tPA (n = 42) compared with 
unmatched patients with acute ischaemic stroke managed conservatively (n = 882) 
  tPA non-tPA 
Education     
 - School (years) 10 (8.5 - 12) 8 (6 - 10) 
 - Tertiary 6 (14.3%) 57 (6.5%) 
Income     
 - Employed 17 (40.5%) 228 (25.9%) 
 - Grant 20 (47.6%) 432 (49%) 
Housing     
 - House 41 (97.6%) 736 (83.4%) 
 - Shack 1 (2.4%) 96 (10.8%) 




















Figure 1: Referral sources of patients recieving tPA and those who were managed 
conservatively 




Figure 2: Early neurological outcomes grouped by severity 


















Figure 3: Proportion of patients achieving early neurological improvement (NIHSS ≥ 4 




Figure 4: Proportion of patients with symptomatic intracranial haemorrhage and 
mortality in the GSH cohort and other trials,6, 19 as well as observational studies.7, 8, 9, 
15, 16, 13, 14, 17 
Data are %. SICH = symptomatic intracranial haemorrhage. Percentages in red = 3 
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Early outcomes of thrombolysis for acute ischaemic stroke in a 
South African tertiary care centre 
Sean Wasserman, Alan Bryer 
Background. Stroke Is an Important cause of death and dlsabUity 
in sub-Saharan Africa. Recombinant tissue plasminogen activator 
(tPA) thrombolysis is effective in treating acute ischaemic stroke, but 
may not be a viable option in developing countries. 
Methods. We assessed the short-term outcomes and safety oflPA 
for the treatment of stroke 31 Groote Schuur Hospital from the year 
2000. Patients with a clinical diagnosis of acute stroke with onset 
of stroke symptoms within 4.5 hours of recelving thrombolysis 
were Included. Exclusion criteria were based on the National 
Institute of Neurological Di>orders and Stroke (NINDS) rl-PA trial 
protocol (upper age limit was 7S years) . Primary outcomes were 
the proportion of patients achieving significant early neurological 
recovery defined as an Improvement of 4 or more points on the 
National Institutes of Health stroke scale (NIHSS) score and 
functional independence defined as a modified Rankin score of 2 
Stroke is an important cause of dl'ath and disability in sub_Saharan 
Africa, where It was estimated that 355 000 stroke deaths occurred 
in 2001,' witb a similar age-specific prevalence to developed 
countries,' but resulting in much higher levels of disability.' 
Cerebrovascular disease is a growing problem in SQuth Africa,' 
and places a heavy burden on family carers In poor socioeconomic 
environments.~ 
Thrombolysis with recombmant tissue plasminogen activator (tPA, 
alteplase) is the only effective specific trl'atment for acute ischaemic 
stroke. The landmark National Institute of Neurological Disorders 
and Stroke (NINDS) rt-PA trial' in the USA in 1995 demonstrated 
that patients receiving this intervention were 30% more likely 
to survive with minimal disability resulting in a 12~ absolute 
Increase In the proportion having excellent functional outcomes 
at 3 months. The benefits 01" thrombolysiS have been consistently 
reproduced when used in routine clinical practice across different 
patient populations. I·. Although its use increases rates of intracranial 
haemorrhage, thrombolysis hu no Impact on overall mortallty.'o 
Net benefit can be achieved iftPAisadministeredwithin4.5hours 
of onset of stroke symptoms." This narrow window of opportunity 
represents the largest obstacle to more widespread use because of 
Inefficient public transport systems and low levels of awareness 
about stroke." This and other issues, such as cost and the availability 
of resources required to administer this treatment, have caused 
concerns that thrombolysis may not be a viable option for treating 
Dtpart~'d of Mtdtdnt. Croote .&h.~, Uosp!taJ and u..t",nlly otOlpe Thw~ 
~an Wm.trman, Mil 018 
Stroke Unll. DtvIsion of Neurology. Drpart~nI of Medldnt. Cmole Schuur U"'p!1II1 
and U~lvtm". ofOlpt TOIII~ 
Alallilrytr, PhD 
or less at discharge. The primary safety measures were the rates of 
symptomatic intracranial haemorrhage (SICH) and death . 
Resulls. From January 2000 to February 2011 42 patients were 
thrombolysed, with a mean time to tPA infusion of 160 minutes 
(standard deviation (SO) SO, range 60 - 270). By discharge the 
median NIHSS score fell from 14 (interquartile range (IQR) 10.5-
17) to 7.5 (IQR 1 _ 15),28 (66.7%) achieved Significant neurological 
improvement, and 17 (40.5%) were functionally independent. Two 
patients (4.8%) suffered SICH and there were 3 (7.1%) deaths. 
umdusion. Thrombolysis in routine clinical practice in a South 
African setting has similar safety and I'arly efficacy outcomes to 
controlled trials and open-label studies I  developing and developed 
countries. 
stroke in developing countries. However, there is growing evidence of 
of its comparable efficacy and safety when used In these settlngsY·11 
The new South African national stroke guidelines recommend 
tPA as treatment for acute ischaemic stroke within 4.5 hours of 
symptom onset." However, there are no published data on the use of 
thrombolysis In Africa. We aimed to evaluate the early outcomes and 
safety of this intervention in a South African setting. 
Methods 
This was a prospective, open, observational study of all patients 
receiving tPA for acute ischaemic stroke at Groote Schuur Hospital 
(GSH) from the year 2000. The hospital has a comprehensive stroke 
unit as defined by the national stroke guidelines. 
Patient ellglbl1lty was defined by the Stroke Unit pr(){ocol and 
included patients with a clinical diagnosis of acute stroke in whom it 
was ascertained that the time of onset of stroke symptoms was within 
3 hours of receiving thrombolysis. After publication of the ECASS III 
trial" In 2008 this time window was extended to 4.5 hours. Exclusion 
criteria were based on the N1NDS rt-PA trial" protocol (in our study 
the upper age limit was 75 years), which broadly restricts eligibility 
to those without evidence of intracranial blood on baseline computed 
tomography (cr) scanning, low risk ofblecdlng, and those without 
rapidly resolving symptoms or severe neurological deficit (National 
Institutes of Health stroke scale (NIHSS) >25). 
Baseline and demographic characteristics, stroke type and severity, 
time Intervals, risk faClors, and medication history were recorded. 
Neurological impairment and functional disability were assessed 
on arrival and at discharge using the NIHSS score and the modified 
Rankin scale (mRS~ respectively. cr scans were performed at 
baseline and within 36 hours of thrombolysis, or on evidence of 
clinical deterioration. 
The primary outcome measure was the proportion of patients 
achieving significant early neurological recovery defined as an 
Improvement of 4 or more points on the NIHSS score at discharge. 
The safety endpoint was the rate of symptomatic intracranial 
haemorrhage (SICH) and death. SICH was defined according to 
the NINDS rt -PAlCochrane crlteriaOl as any new evidence of 













intracranial blood on cr or magnetic resonance imaging (MRI) 
accompanied by a neurological deterioration of 4 or more points 
on the NIHSS score from baseline. Functional independence (Le. an 
mRS score of 0 - 2) or an improvement of two or more points on the 
mRS achieved at discha rge were secondary outcomes. 
TIle proportion of patients with SICH, mortality, independence, 
and neurological improvement were calculated and compared with the 
corresponding proportions in the alteplase arm of the NINDS rt-PA 
and ECASS III trials, and with observational studies in developed and 
other developing count ries. 
Demographic profiles were compared with a cohort of unmatched 
patients who suffered isdlaemic strokes but who were managed 
conse rvatively in our stroke unit. The laller patients were ineligible 
for thrombolysis, and thei r data were recorded in the same register as 
those who received tPA from Janua ry 2000 to April 2006. 
Written informed consent was obtained either from the patients 
o r from a close family member. Alteplase was administered in 
consultation with the attending neurologist or stroke physician. An 
intravenous (IV) dose of alteplase (0.9 mgfkg, with 10% given as a 
bolus followed by an infusion over I hour) was administered in the 
emergency department after the baseline cr scan was reviewed. 
Selected patients received intra-arterial (lA) alteplase. 
This study was approved by the Ucr-GSH Hwnan Research Ethics 
Committee (Ref. 38612011). 
Results 
Forty-two patients were thrombolysed at GSH from January 2000 to 
February 2011 . Their mean age was 60 (SO 12.26, range 24 - 79) and 
the median baseline NIHSS score was 14 (interquartile range (IQR) 
10.5 - 17). Approximately 60% were clinically assessed to have la rge-
vessel atheroembolic aetiologies. Thirty-six (85.7%) received IV tPA, 
4 (9.5%) received IA tPA and 2 (4.8%) received bridging treatment 
with IV tPA followed by an endovascular procedure including IA tPA. 
Three (7.1%) patients were over the age of 75 years. 
Table I . Baseline clinical cha racter istics o f patients receiving 
tPA (N=42) 
Ya riable 
Age (years), median OQR) 62 (52 - 67.5) 
Male sex, % 54.8 
Married, n (%) 24 (57.1) 
Systolic blood pressure (mmHg), median (IQR) 149 (134 - 170) 
Diastolic blood pressure (mmHg), median (IQR) 84 (76 - 90) 
Degree of neurological severity (NIHSS) 14 (10.5 - 17) 
Mild (0 - 7). n (%) 2 (4.8) 
Moderate (8 - 14), II (%) 19 (45.2) 
Severe (~ 1 5),n (%) 18 (42.9) 
Cause of stroke 
large-vessel atheroembolic, II (%) 25 (59.5) 
lacunar, n (%) 3 (7.1) 
Cardioembolic, II (%) 9 (21.4) 
Other, n (%) 3 (7.1) 
Unknown, n (%) 2 (4.8) 
Stroke onset to treatment time (min), 
mean (SD) 160 (±SO) 
Table 2. Demographic character istics o f pati ents receiving 
tPA compared with unmatched patients with acute 
ischaemic stroke ma naged consen 'atively 
Education 
&hool (years), median (IQR) 
Tertiary, n (%) 
Irn:ome 
Employed, n (%) 
Grant, II (%) 
Housing 
House,n (%) 


















Table I shows clinical data, including stroke type and severity. 
NIHSS data were complete at discharge in 39 (93%) patients and the 
mRS was recorded for all patients. The mean time to tPA infusion was 
160 minutes (SO SO, range 60 - 270). Most patients (29, 72.5%) were 
thrombolysed within 180 minutes. Median duration of hospital stay 
was 12 days (lQR 8 - 15.8). Table 2 compares demographic data of the 
patients receiving tPA, and unmatched patients with acute ischaemic 
stroke managed conservatively in the same unit. Of the patients who 
received thrombolysis, 25/42 (59.5%) arrived at hospital using their 
own transport; the next most common referral source was from 
private hospitals (5/42, 11.9%) (Fig.I) . 
Fig. 2 illustrates early neurological outcomes grouped by severity. 
~ 
-~
Fig. 1. Riferral sources of pa1irnts reuiving tissue plasminogen actiYlltor 
(IPA) and those managed wnscrva1ively. 
Admission 
Discharge 
48" 19" 11" 
• Mild • Mode ... t . • Death unknown 
Fig. 2. Early neurological outromesgrouped by severity (mild = NIHSS 0 - 7; 
moderate = NlHSS 8 - 14; severe = NIHSS ~15). 















Fig. J . Proportion of pa1irnls achieving enrly nruroiogicaJ improvement 
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Fig. 4. Proportion of patients with symptomatic intracranial hlUmorrhage 
and mortality in lire GSH cohort and other trials,"" as well as obslTmfionai 
studies!-~IJ-IT SICH = symptomatic intracranial hlUmorrhage. Percentages 
in red = 3-month data, in black = dala al discharge. 
The median NIHSS score fell to 7.5 (IQR 1 IS) by the time of 
discharge. Forty-eight per cent of patients scored in the mild range 
(0 - 7), compared with only 5% on arrival. At discharge 18 (42.9%) 
patients had improved their mRS by 2 or more points and 17 (40.5%) 
were functionally independent. Over half (53.8%) of our patients 
were discharged home. Fig. 3 compares the proportion of patients 
who achieved significant neurological improvement in this study 
with that of other studies. 
Fig. 4 compares our patients and results from other studies for 
SICH (using the NINDS rt -PAlCochrane definition) and mortality. 
Only 2 (4.8%) of our patients suffered SICH. Adverse effects were 
not significantly related to time oftPA infusion, age or stroke severity. 
All three patients aged >75 years experienced bleeding complications 
with one, aged 76, suffering a symptomatic intracranial haemorrhage 
(NIHSS 8). Another, aged 79, had an asymptomatic intracranial 
haemorrhage (NIHSS 28), and the third patient, aged 78, developed a 
femoral haematoma (NIHSS 19). 
At the time of discharge a total of3 (7.1%) patients had died, all of 
whom had admission Rankin scores of 5. Besides the single patient 
with fatal intracranial haemorrhage the deaths were unrelated to 
treatment; one patient died of an acute myocardial infarction, and the 
other from an additional cerebral infarct and nosocomial pnewnonia. 
Discussion 
Two-thirds of our patients achieved significant neurological 
improvement after receiving tPA, which compares favourably with the 
NINDS rt -PA trial.' Smaller studies from other developing countries 
reported similar results.')," The European Medicines Evaluation 
Agency allowed registration of tPA for acute stroke in 2002, on 
condition that an observational safety study be performed to address 
concerns about the applicability of data from randomised controlled 
trials to individuals in daily clinical practice. At 3-month follow-
up, 54.8% of patients in this SITS-MOST cohort were functionally 
independent! compared with 40.5% at the time of discharge in 
our study. Although other studies demonstrated sustained clinical 
benefit of thrombolysis,» this could not be assessed with our study 
design which was limited by a short follow-up period. However, the 
functional outcomes of our patients may be comparable with those 
of the SITS-MOST study as improvement after tPA typically occurs 
early because of vessel recanalisation, and further recovery would be 
anticipated in our surviving patients with rehabilitation in the 90 days 
post discharge. 
Our patients had a lower rate of SICH compared with the NINDS 
rt-PA trial (4.8% v. 6.4%)' and the large open-label SITS-ISfR study 
(8.0% for patients treated between 3 and 4.5 hours and 7.3% for 
patients treated within 3 hours).' Pooled data from five observational 
studies from developing countries show a lower proportion of 
patients suffering SICH, 9/293 (3.1%), but the rates ranged from 0 
to 5.9% between the different centres.')'11 Although the nwnber is 
small and does not represent a significant association, all three of 
our patients over the age of 75 had bleeding complications. Studies 
in the developed world support the safety of tPA in patients over 80 
years." However, more caution may be needed in our setting when 
thrombolysing elderly patients. 
Our in-patient mortality was similar to that of the NINDS rt -PA 
trial (7.4%), but could not be compared with large observational 
studies such as SITS-MOST and CASES as these only reported 
3-month mortality rates. The 7-day mortality of 11 621 patients 
treated within 3 hours in routine practice across Europe was similar 
to ours at 6.S%; the rate for those treated between 3 and 4.5 hours in 
the same registry was 7.5%.' In 3 studies from developing countries 
the mortality at discharge ranged from 0 to 5.9%.'3,'4," 
It is estimated that <2% of patients with ischaemic stroke in our 
hospital drainage area received thrombolysis, which seems comparable 
with data from other developing countries.'"'' However, our reported 
thrombolysis rate is an overestimation for the general population, as 
most patients with acute stroke are managed conservatively at lower 
level facilities where thrombolysis is not available. 
This study was not designed to identify barriers to accessing 
thrombolysis, but inferences may be drawn from our findings in this 
regard. Most patients who qualified for tPA used their own transport 
to hospital, suggesting that delays in the emergency medical services 
transport system may be a cause for arrival outside of the 4.5 hour 
window period. A greater proportion of patients who received 
thrombolysis were employed, and lived in brick houses compared 
with conservatively managed patients, suggesting that those with 
higher incomes are more likely to arrive at hospital within the narrow 
time window required for this intervention. As in other studies,'·~' 
low levels of public awareness of stroke may be another barrier to 
thrombolysis in our setting as reflected by the difference in education 
levels between the patient groups. Certain quarters in South Africa's 
emergency medicine oonununity" and elsewhere are reluctant to 
use tPA for stroke,ll and this may also have contributed to the small 
nwnbers of patients referred from secondary level hospitals. 
A study limitation is the relatively small number of patients with 
ischaemic stroke in the GSH cohort that received tPA. Nevertheless, 
the data indicate that the use of thrombolysis in routine clinical 
practice in a South African setting has similar safety and early 
efficacy outcomes to developed and other developing countries. 
Thrombolysis is specialised and is not available to most South 
Africans. However, its benefits for reducing disability for stroke 
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2. SAMJ INSTRUCTIONS TO AUTHORS 
Manuscripts   
Short items are more likely to appeal to our readers and therefore to be accepted for 
publication.    
 
Original articles of 3 000 words or less, with up to 6 tables or illustrations, should 
normally report observations or research of relevance to clinical medicine. References 
should preferably be limited to no more than 15. Original articles must be 
accompanied by a structured abstract not exceeding 250 words, with the following 
recommended headings: Background, Aims, Methods, Results, and Conclusion.   
 
Manuscript Preparation 
Refer to articles in recent issues for guidance on the presentation of headings and 
subheadings. If in doubt, refer to 'uniform requirements' - www.icmje.org. 
 
Manuscripts must be written in UK English. 
 
Qualification, affiliation and contact details of ALL authors must be provided with 
submissions. 
 
Abbreviations should be spelt out when first used in the text and thereafter used 
consistently, e.g. 'intravenous (IV)' or 'Department of Health (DoH)'. 
 
Scientific measurements should be expressed in SI units except: blood pressure should 
be given in mmHg and haemoglobin values in g/dl (Note: litres is denoted with a 
lowercase l as in 'ml'). Units should be preceded by a space (except for %), i.e. '40 kg' 
and '20 cm' but '50%'. Greater/smaller than signs (> and <) should be placed 
immediately preceding the relevant number, i.e. 'females >40 years of age'. The same 
applies to ± and º, i.e. '35±6' and '19ºC'. 
 
Numbers should be written as grouped per thousand-units, i.e. 4 000, 400 000, 22 












Quotes should be placed in single quotation marks: i.e. The respondent stated: '...' 
 
Round brackets (parentheses) should be used in the text and not square brackets, 
which are reserved for denoting concentrations or insertions in direct quotes. 
 
General Formatting 
The manuscript must be in Microsoft word of RTF document format. Text must be 
single-spaced; in 12-point Times New Roman font; employ italics and bolding rather 
than underlining; and be free of unnecessary formatting (e.g. text in boxes, with the 
exception of Tables). 
 
Figures - see ILLUSTRATIONS below. Figures must be numbered (1,2,3...) and must be 
referred to in the text e.g. 'Refer to Fig. 1'. Figures legends must appear as such: 'Fig. 
1. Brief history of the development of...' 
 
Tables - may be embedded in the manuscript file or provided separately as 
'supplementary files'. Tables must be numbered in Roman Numerals as such: Table I, 
Table II, etc. Footnotes must be indicated with the use of the following symbols (in 
order): * † ‡ § ¶ || then ** †† ‡‡ etc. 
 
Illustrations 
Figures consist of all material that cannot be set in type, such as photographs and 
line drawings. If any tables or illustrations submitted have been published elsewhere, 
the author should obtain written consent to republication from the copyright holder 
and the author(s).  
 
Please note: All illustrations/figures/graphs etc. must be of high resolution/quality: 
300 dpi or more is preferable but images must not be resized to increase resolution. 
Raw (unformatted/uncompressed) images must be attached as 'supplementary files' 
upon submission, and not embedded in the accompanying text document. TIFF and 











compression. Figures may also be provided in high-quality uncompressed PDF format. 
For figures/graphs prepared in Microsoft powerpoint/excel, the original workbook 
must be provided.  
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1.1 Project title 
Early outcomes of thrombolysis for acute ischaemic stroke in a South African tertiary 
care centre. 
 
1.2 Purpose of the study 
The primary objective of this project is to evaluate the early outcomes and safety of 
thrombolysis for acute ischaemic stroke in routine clinical practice in a South African 
public healthcare setting. In order to determine this, we will analyse data 
prospectively entered into the UCT Stroke Database over the past 11 years. Our 
findings will be compared with published results of trials and large observational 
studies from developed countries as well as with those from open-label use in 
developing regions. We also hope to identify potential factors that limit the 
application of this therapeutic option and ways in which it may be improved.  
 
1.3 Background 
It has been estimated that 355 000 stroke deaths occurred in sub-Saharan Africa in 
2001 [Connor, 2007], with an overall prevalence ranging from 0.07 to 0.3% [Dalal, 
2011]. That year the SASPI study group documented an age-specific prevalence of 
598 per 100 000 at the Agincourt site in rural Limpopo province, which is similar to 
that recorded in developed countries [Connor, 2004].  
 
Morbidity and mortality of stroke in sub-Saharan Africa is high. Sixty six percent of 
stroke survivors from the Agincourt district site required assistance with at least one 
activity of daily living [Connor, 2004]; much higher compared to stroke survivors 
from a New Zealand community, only 22% of whom required help with self-care 
activities [Bonita, 1997]. In three Tanzanian sites the 15 to 64 years age-adjusted 
stroke mortality rates were statistically higher than in England and Wales [Walker, 
2000]. An observational study performed at a rural site in Kwazulu-Natal showed an 
overall mortality of 30% at 3 months after stroke, much higher than the all stroke 











severe disability, placing a burden on family carers in a poor socio-economic 
environment [Wasserman, 2009].  
 
An extended follow-up of the Agincourt community over the period 1995 to 2005 
found that deaths due to stroke, ischaemic heart disease, and hypertension had 
increased by 65% (1.65 [0.99 - 2.76]; p = 0.056) in adults aged over 65 [Tollman, 
2008], providing evidence that cerebrovascular disease is a growing problem in 
South Africa. Connor et al concluded from a systematic review that although the 
prevalence of stroke is lower than in high-income regions, disabling stroke 
prevalence may be at least as high in sub-Saharan Africa [Connor, 2007]. This is 
consistent with a so-called bipolar health transition where infectious and non-
communicable diseases co-exist and both contribute significantly to chronic illness 
[Frenk, 1989]. There is evidence that hypertension and obesity are highly prevalent 
in rural and urban [Rayner, 2010] areas in South Africa, and this, together with 
increasing rates of non-communicable disease, re resents the early phase of a 
health transition in the region. Data from the SASPI study also demonstrated the 
presence of considerable sub-clinical atheroma in a rural population [Thorogood, 
2007], an indication of progression to later phases of the transition characterised by 
complications of atherosclerotic disease. South Africa may thus be facing an 
emerging epidemic of vascular disease which may potentially place a significant 
economic burden on the country. 
 
A number of studies have been conducted in South Africa with the aim of identifying 
factors to be included in a model of stroke care for both rural and urban 
communities. In rural areas the development of more effective home-based care 
and training of family carers may be important interventions [Wasserman, 2009], but 
it is indisputable that the management of patients in a dedicated stroke unit (SU) 
reduces mortality and disability after acute stroke. The latest Cochrane review 
published in 2007 showed a 14% reduction in death (OR 0.86; 95% CI 0.76 to 0.98; p 
= 0.02) at a median time of one year after acute stroke. This analysis also 
demonstrated that patients treated in SUs are more likely to be alive and 











95% CI 0.73 to 0.92; p = 0.0006) compared with controls from 31 trials involving 
almost 7000 patients [Stroke Unit Trialists’ Collaboration, 2007]. A local study 
demonstrated that improved outcomes can be achieved by managing patients in a 
multidisciplinary SU without the requirement of additional funding and staff [de 
Villiers, 2009].   
 
Thrombolysis with recombinant tissue plasminogen activator (t-PA, alteplase) is the 
only effective specific treatment for acute ischaemic stroke. The landmark trial in 
1995 demonstrated that patients receiving this intervention were 30% more likely to 
survive with minimal disability giving a 12% absolute increase in the proportion 
having excellent functional outcomes at 3 months [NINDS, 1995]. Subsequent large 
observational trials and meta-analyses have provided robust evidence for the 
efficacy and safety of alteplase for treatment of acute ischaemic stroke. The latest 
Cochrane review included 26 placebo-controlled trials with a variety of thrombolytic 
agents and ranges of times from stroke onset to treatment involving 7152 patients 
[Wardlaw, 2009]. Over half of the data was from trials testing tPA. They found that 
treatment within three hours of stroke significantly reduced the proportion of 
patients who were dead or dependent (mRS ≥3) 3 to 6 months after stroke (OR 0.71, 
95% CI 0.52 to 0.96). 
 
The benefits of thrombolysis have been consistently reproduced when used in 
routine clinical practice across different patient populations. The CASES study [Hill, 
2005] collected data on stroke patients from 60 Canadian centres over the period 
February 1999 to June 2001. A total of 1135 patients were thrombolysed with tPA, 
with 36.8% achieving the pre-defined excellent outcome (adjusted mRS of 0 to 1) at 
3 months. The SITS-MOST study included 6483 patients from 285 European centres 
between the years 2002 and 2006. Complete recovery at 3 months was seen in 
38.9% (95% CI 37.7 to 40.1) of patients in SITS-MOST compared with 42.3% (95% CI 
37.8 to 47.0) in randomised controlled trials. At the time of discharge the median 
NIHSS score had fallen to 4 (IQR 1 – 11). There were no significant differences in the 
rates of complete recovery or symptomatic intracranial haemorrhages between 











Although its use comes at a cost of increased rates of intracranial haemorrhage, 
thrombolysis has no impact on overall disability or mortality. The 2009 Cochrane 
review of thrombolysis trials demonstrated no statistically significant adverse effect 
on death (OR 1.13, 95% CI 0.86 to 1.48). The overall benefit of tPA was achieved 
despite an increased risk of symptomatic intracranial haemorrhage (SICH) which 
occurred in 7.7% of patients receiving thrombolysis versus 2.1% of those allocated to 
control (OR 3.49, 95% CI 2.81 to 4.33). Although there was a trend towards higher 
mortality in the first ECASS trial, these patients were treated with a higher dose of 
alteplase up to 6 hours after stroke onset and the deaths occurred mainly in those 
with major early infarct signs on CT [Hacke, 1995]. In the subsequent ECASS II trial 
using a tPA dose of 0.9mg/kg, there was no difference in overall mortality at both 7 
days and 3 months (10.3% in the alteplase group) compared with control, despite a 
2.5 fold excess in SICH with alteplase [Hacke, 1998]. In the CASES study SICH 
occurred in 4.6% (95% CI 3.4 to 6.0), while in SITS-MOST the proportion of patients 
with SICH according to the NINDS/Cochrane definition was 7.3% (95% CI 6.7 to 7.9) 
compared with 8.6% (95% CI 6.3 to 11.6) in the pooled data from controlled trials, 
demonstrating that there is no increased risk of SICH with thrombolysis used in 
routine clinical practice.  
      
The efficacy of thrombolytic therapy has a clear inverse association with the interval 
between onset of stroke symptoms and administration of treatment. An analysis of 
the NINDS study data showed a significant improvement of outcomes at both 24 
hours and at 3 months in the group given alteplase between 0 and 90 minutes of 
stroke onset-to-treatment (OTT) compared with those thrombolysed at 91 to 180 
minutes [Marler, 2000]. Similar findings were demonstrated in a pooled analysis of 
2775 patients from 6 randomised trials of tPA given over a range of OTTs from 3 to 6 
hours [Hacke, 2004]. The benefit of tPA was shown to extend beyond 3 hours with 
demonstration of an odds ratio of 1.40 (95% CI 1.05 to 1.85) for favourable outcome 
for those treated within 181 to 270 minutes. Although SICHs were seen more 
frequently in the tPA group (5.9% versus 1.1% p < 0.0001) and in older patients 











This led to ECASS III, a randomised placebo-controlled trial designed to test the 
efficacy and safety of alteplase administered between 3 and 4.5 hours after the 
onset of acute ischaemic stroke [Hacke, 2008]. In this study 821 patients from 130 
European sites were randomised between July 2003 and November 2007 to receive 
either alteplase 0.9mg/kg or placebo between 3 and 4.5 hours after stroke onset. 
Compared with placebo, significantly more patients in the alteplase group achieved a 
favourable outcome (52.4% versus 45.2%; OR 1.34 (1.02 - 1.76), p = 0.04). This 
represented an absolute improvement of 7.2%, and translates into 1 patient having a 
favourable outcome for every 14 patients treated in the extended time window. 
Despite the significantly higher rates of total (27.0% vs. 17.6%; OR 1.73 (1.24 - 2.42) 
p = 0.001) and symptomatic intracranial bleeding (2.4% vs. 0.2%; OR 9.85 (1.26 - 
77.32) p = 0.008) in the patients who received thrombolysis, there was no difference 
in 3 month mortality between the two groups: 7.7% versus 8.4% for placebo; OR 
0.90 (0.54 - 1.49), p = 0.68.  An updated pooled analysis incorporating data from 8 
trials (including ECASS III) and 3670 patients published in 2010 confirmed that 
benefit is seen with tPA up to 4.5 hours after onset of stroke symptoms [Lees, 2010]. 
 
As a result of the above evidence, the South African Stroke Society officially 
endorsed thrombolysis with recombinant tissue plasminogen activator (tPA) within 
4.5 hours of symptom onset as the standard of care for acute ischaemic stroke 
[Bryer, 2010].  
 
tPA thus represents a major therapeutic breakthrough in the treatment of stroke. 
However, its impact on the general population has been limited, mainly by the 
narrow time window allowed for administration, but also as a result of the various 
other restrictions. The CASES study estimated that only 1.4% of 90200 patients with 
ischemic stroke received thrombolysis over the 2.5 year study period [Hill, 2005]. 
Others have estimated that only between 1.8 to 3.0% of all ischaemic stroke patients 
are treated with tPA in the United States [Qureshi, 2005; Kleindorfer, 2008]. In an 
analysis of 495186 ischemic stroke admissions in the USA between the years 2005 
and 2007, only 2.4% received tPA [Kleindorfer, 2009]. A systematic review of studies 











found that in European studies the proportion of patients arriving within 3 hours of 
stroke onset ranged from 25 to 61%, in the USA/Canada 30 to 56%, and in Asia 24 to 
50%. Delay to treatment over 3 hours or unknown onset time was the commonest 
reason (up to 94%) for tPA ineligibility. The most consistent pre-hospital barrier was 
the patient’s or family’s poor knowledge of stroke symptoms [Kwan, 2004]. Another 
US review also identified lack of public knowledge of stroke symptoms and tendency 
not to seek immediate care as major factors in treatment delay [Bambauer, 2006]. 
The fear of emergency physicians about the increased risk of intracerebral bleeds 
and perceived lack of efficacy with tPA is another obstacle limiting its use. A survey 
found that 40% of emergency department physicians would not use alteplase for 
acute stroke, with 65% citing risk of intracerebral haemorrhage as the reason for not 
using tPA, and 23% of physicians citing perceived lack of benefit [Brown, 2005]. This 
view also seems to be prevalent in South Africa. The head of the emergency 
medicine department at UCT recently published a letter claiming that “there is no 
compelling evidence to support the use of tPA in stroke; its use beyond 3 hours is 
dangerous, and it should not form part of national guidelines”[Lahri, 2001]. 
 
Because of the potential problems of cost and limited availability of required 
facilities, there have been concerns that thrombolysis may not be a viable option for 
treating stroke in developing countries. This treatment option is only available in a 
minority of developing countries including Brazil, Argentina, Senegal, Iran, Pakistan, 
China, Thailand, and India; and even in the places where it is offered, the number of 
patients receiving alteplase for stroke is very low [Durai Pandian, 2007].  
 
However, despite limited experience with this agent, there is growing evidence of its 
comparable efficacy and safety when used in these settings. A hospital in the low 
income and densely-populated Indian region of Uttar Pradesh was able to 
thrombolyse 32 of 584 patients (≈5%) with acute stroke over a 3 year period from 
September 2004. At 48 hours 65.6% had improved their NIHSS score by 4 or more 
points. There was only 1 symptomatic intracerebral haemorrhage and 1 death 
unrelated to treatment. At one month follow-up a favourable Barthel index score of 











study from New Delhi of 54 patients with comparable baseline characteristics 
showed similar positive results. None of these patients suffered symptomatic 
intracranial bleeds and there were no mortalities at discharge; 65% had significantly 
improved NIHSS scores by 48 hours [Padma, 2007].  
 
The safety outcomes of 21 patients thrombolysed at two tertiary hospitals in Karachi 
were less reassuring. In this group the mean age was 62 (range 27 to 77) years, the 
mean time delay from stroke onset to tPA infusion was 169 minutes (95 to 200), but 
stroke severity was not reported. A total of 4 patients (19%) died, 3 of a fatal 
intracranial haemorrhage. There were protocol violations for all patients who had 
complications [Wasay, 2010]. The small numbers and retrospective design were 
major limitations, and the findings of this study should be interpreted in this context. 
 
The largest published cohort of stroke patients receiving tPA in Asia is from three 
referral hospitals in Ho Chi Min City, Vietnam. Prospective data was collected on 121 
patients, representing 2% of the total number of patients who presented with acute 
ischaemic stroke over the period 2006 to 2009. Just over 40% of the patients could 
not afford a second ampoule of alteplase and were treated with a lower dose, mean 
0.62mg/kg. In the lower dose group 56.3% had achieved functional independence 
(mRS 0 to 1) by 3 months, the proportion in the standard dose group was 34.2%. The 
rate of symptomatic intracranial haemorrhages was higher in the standard dose 
group at 5.5% versus 2.1% in those receiving lower dose tPA. There were a total of 
10 deaths in the cohort (8.3%), only 2 (1.7%) resulting from bleeding complications 
[Nguyen, 2010]. 
 
The results of two prospective studies of tPA in Thailand showed comparable results 
to published trials from developed countries. The first reported 34 cases of severe 
stroke (median NIHSS score 20) thrombolysed over the period 2001 to 2004. 
Significant neurological improvement was achieved by 70.6%, with only 2 cases 













The second Thai study evaluated the introduction of an acute stroke support 
network in a community-based hospital. The network covered 25 rural, 2 regional, 
and 2 provincial hospitals, all located within 80 km of the referral centre. After 
arrival at their local hospital, usually by private transport, patients are immediately 
screened by trained clerks and nurses using a modified Cincinnati pre-hospital stroke 
screen. If acute stroke with onset less than 3 hours is suspected, the stroke fast track 
is activated whereby patients are immediately sent to the emergency department 
for baseline investigations, insertion of IV lines and urgent transfer arranged to the 
referral centre for CT scanning and assessment for thrombolysis. Over a 16 month 
period from October 2007, 458 patients were admitted with acute ischaemic stroke. 
A high proportion (21%) received IV t-PA, and of these 100 patients, 59 had been 
transferred from a hospital in the acute stroke referral network. A total of 41% of the 
referred patients were thrombolysed, and the mean OTT was 160 minutes (range, 
60-270 minutes). At 3 months 42% of patients had achieved excellent recovery (mRS 
0-1) with a mortality rate of 14%. Only 2% of patients had symptomatic intracerebral 
bleeding [Muengtaweepongsa, 2010].  
 
These data indicate that integration of an acute stroke referral network into a 
protocol of IV thrombolysis for acute stroke is feasible in a developing country, and 
helps to increase the rate of tPA use.   
 
There are no published data on thrombolysis for acute ischaemic stroke in Africa. We 
therefore seek to investigate whether tPA can be safely used in routine practice at a 
tertiary stroke referral centre in South Africa, and if this results in the early 
neurological improvement seen with its use in other settings.     
 
2. METHODOLOGY 
2.1 Study design 
Review of data captured prospectively over the period January 2000 to February 
2011 for patients receiving tissue plasminogen activator (tPA) for acute ischaemic 












2.2 Characteristics of the study population 
GSH is a tertiary referral centre in the Western Cape, but also provides secondary 
level care for patients living in its direct drainage areas; it thus receives referrals 
from other centres as well as self-referrals. The hospital supports a community of 
predominantly low to middle socio-economic status from an urban environment. In 
this population there appears to be a high prevalence of risk factors for 
cardiovascular disease: 26% of general medical admissions at Groote Schuur have an 
underlying diagnosis of diabetes, hypertension, ischaemic heart disease, chronic 
kidney disease or previous stroke (Peter Raubenheimer, personal communication, 
unpublished data from GSH database). With few exceptions, every patient 
presenting with acute stroke is initially assessed in the Emergency Department (ED) 
and subsequently referred to either the general medical ward or stroke unit for 
admission and further care.  
 
Patients are selected for thrombolysis on the basis of clinical eligibility criteria 
defined by the Stoke Unit Protocol (Appendix F). Men and women between the ages 
of 18 and 75 years with a clinical diagnosis of acute stroke and certain time of onset 
within the preceding 3 hours are potential candidates. Deviations from this protocol 
are allowed for selected patients over the age of 75 years. This is based on recent 
data from Germany and Canada showing no increase in severe intracranial 
haemorrhage in very old patients [Berrouschot, 2005; Mateen 2010]. After 
publication of the ECASS III trial in 2008 the OTT window was extended to include 
patients presenting within 4.5 hours. The completion of specifically-designed 
consent form by the patient or a legally-competent representative is required prior 
to the administration of tPA.  
 
2.3 Recruitment and enrolment 
This analysis will include all patients who received tPA at GSH over the period 
January 2000 to March 2011. Patients are recruited by virtue of being selected to 
receive thrombolysis according to the Stoke Unit Protocol criteria, and their clinical 
details are prospectively captured in the UCT Stroke Database. Eligibility for 











consultation with an attending neurologist. Patients receiving intra-arterial tPA are 
also included in the analysis, and the decision to use this route of administration is 
made in each case by a neurologist together with a neurosurgeon.  
 
Exclusion criteria are clearly defined by the existing GSH Stroke Unit guidelines which 
are based on those used in the NINDS-tPA trial. Contraindications to thrombolysis 
broadly include any evidence of intracranial haemorrhage on brain imaging, 
depressed level of consciousness or rapidly improving symptoms, a history of stroke 
within the preceding 3 months, and a high risk of bleeding (the detailed criteria are 
included in Appendix F).  
 
2.4 Treatment protocol 
Those eligible for intravenous (IV) thrombolysis are given alteplase at a dose of 
0.9mg/kg (maximum 90mg) with 10% of the dose given as a bolus followed by the 
remainder given as an infusion over 60 minutes. The administration of 
anticoagulants or anti-platelet agents is not allowed within 24 hours of thrombolytic 
treatment. Initial monitoring takes place in the ED and thereafter patients are 
transferred to either the SU or a high-care environment for 24 hours. Safety 
monitoring is performed by regular clinical examinations with the aim of detecting 
bleeding or neurological dete ioration. Follow-up CT scans are done routinely on all 
patients at some time before discharge and after any clinical suspicion of intracranial 
haemorrhage.  
 
2.5 Research procedures and data collection methods 
Patient data is captured by the attending doctor at the time of discharge from the SU 
on a specifically designed proforma (Appendix A). All doctors involved in the 
assessment of thrombolysis patients have received some training on how to 
administer the various scoring systems and are given detailed guidelines on their 
use.  
 
Study numbers are assigned automatically by the database and the following 











• Demographic details 
- Hospital folder number 





• Risk factors for stroke including co-morbid medical conditions 
• Time intervals between symptoms, presentation, and infusion of tPA 
• Referral sources 
• Stroke subtype according to TOAST classification (Appendix C): 
- Large vessel atherothromboembolic (probable/possible)  
- Cardioembolic (probable/possible) 
- Small vessel/lacunar (probable/possible) 
- Acute ischaemic stroke of other aetiology (probable/possible) 
- Acute ischaemic stroke of unknown cause (single or more than one 
likely aetiology) 
• Baseline functional and neurological deficits using standardised scoring 
systems:  
- Modified Rankin Scale (mRS) as a measure of functional disability 
(Appendix D) 
 Mild = 0 to 1 
 Moderate = 2 to 3 
 Severe = 4 to 5 
- National Institute of Health Stroke Scale (NIHSS) as a measure of 
neurological impairment (Appendix E) 
 Mild = 0 to 7 
 Moderate = 8 to 14 
 Severe ≥ 15 
• Details of investigations and management 











• Outcomes at discharge measured using mRS and NIHSS scores 
- Functional independence is defined as an mRS score of 0 to 2 
- Significant neurological improvement is defined as an improvement 
on the NIHSS scale of 4 or more points 
• Any complications resulting from the administration of tPA  
- Symptomatic intracranial haemorrhages 
 Defined according to the NIHSS trial and Cochrane review as 
any haemorrhage detected on CT or MRI scanning 
accompanied by a deterioration in neurological function of 4 
or more points on the NIHSS scale 
- Asymptomatic intracranial haemorrhage 
- Any extracranial bleeding 
- Other complications such as angioedema or hypotension 
• Deaths from all causes 
- mRS score of 6 is death 
• Duration of hospital stay 
• Discharge destination 
 
2.6 Data analysis 
The UCT Stroke Database was established in the year 2000 in order to collect clinical 
information from all patients with a diagnosis of stroke admitted to the stroke unit 
(SU), including the details of any patient receiving tPA. Faculty of Health Sciences 
Human Research Ethics Committee approval was obtained for this (REC Ref 
189/2002) and is valid until 15 July 2012. All data is entered into a pre-designed 
Microsoft Access Stroke Unit Database and coded for further analysis. For the 
purpose of this study, each patient data form will be checked for completeness and 
any missing information recovered by a retrospective folder review by the 
investigators. Data will be analysed using 1-way ANOVA and paired student's t-test 













3. ETHICAL ISSUES 
3.1 Description of risks and benefits 
The use of tPA for thrombolysis in selected patients with acute ischaemic stroke is 
considered to be standard of care, and has been endorsed in recently published 
stroke management guidelines by the South African Stroke Society [Bryer, 2010]. 
This survey does not involve randomisation or control substances, and patients are 
informed of the risks and benefits of the intervention during the consent process. 
Participation in this observational study is dependent on the patient consenting to 
the treatment on its own merits and in no way influences the management decisions 
taken with regard to individual patients. The alternative to this intervention includes 
the same stroke care provided to those patients who do not otherwise qualify for 
thrombolysis. The harm: benefit ratio of tPA for stroke is described in section 1.3.   
 
3.2 Informed consent process 
In all cases informed consent for the use of tPA is obtained before the therapy is 
administered. In cases where the patient lacks capacity to consent, consent is 
obtained from a suitable relative as per standard hospital guidelines. The consent 
process is performed by the clinician administering the treatment, and is 
documented on a specifically designed form which also includes an explanation of 
the risks and benefits of the intervention (Appendix B).     
 
3.3 Privacy and confidentiality 
Personal and medical information of the participants is only accessible to the 
attending doctors and the study investigators. All names are erased and variables 
have been coded in the dataset used for statistical analysis. The UCT Stroke 
Database is only accessible to the investigators.  
 
3.4 Conflicts of interest 
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5.1 Appendix A: Data sheet 
UCT STROKE DATABASE 1 Hospl .. l; 
Oumame: 
FIB! name: 
Hospital fold ... number: 
109·; 
Sex: 1 r,. rl. ' 
~_~~.~M~.~le _____ ~~~F~e~m=81~. __ ~ 
o.re 0' Birth ,-I -,-1'--1..1 -"1'--1..1 -" ---
Elhnle Group: l.I ____ o__ Wh __ "_. ______ o __ B_Iacl< ________ o __ CO __ ,OU __ red _____ o:....:._,nd_Ia_ ... _Asl __ 8_n ____ -..l 
Ad""',,: 
Telephone: Home; Wor1c _______ _ Cell: 
Oat. ofadmluion: ' .1 , I , I , DATE of STROKE! , I I I I 'Time of STROKE: __ h_ 
Av-oke with deficit Dyes Dna Onset uni<no'Ml: 0 yes ono 
Duration of Interval between stroke onset and hospital medical a.se.ment IL _________ .....J 
Referral to hospital: 0 self 0 GP 0 Day 0 Secondary Dother:. _______ _ 
hospital hospital 
Medical Insurance: Dyes Ono 
M.rt .. IS .. ru·L' __ -=O=-M_._m_·oo __ '_com __ m_o_~ _ aw ______ ~D~s_i~~le ______ o~_~_~_~ _______ O __ D_w_o~ _____ ~ 
Sole Bread W1n_ l.1_O __ yes _____ O __ n_o __ ~ 
Housing: R House/A.t 
..... Serviced Sheck (tOilet plus lap) 
[J Unserviced Shack 
If Yes then state number of financial 
dependents Including partner: 
8" Dormhory ( Hostel ( single room Other - Speclfy; _________ ;:==.. 
Number 0' peopl.IM~ In dwelling: LI ____ .J 
Number of rooms usOO for sleeping In the dwelling: 
Education: 
Yeal$ of schooling passed: 1 
Years of tertlary eduC<llion p'-a.-""-: 'I :'-.-., 
Employment: 
Employad: o professionaVmanag.rlal 
o middle management 
o manual foremanlskilloo artisan 
o fanner - Iallle fann 
o subsist.nce fanner 
o cI.rical/ .. m~skilioo 
o unskilledllnfonnal sector trader 
Unemployed: o looking for wor1< 
o unemPloyed by choice e.g. home maker 
o full time student 
o social pensioner - on disability grant or 













Risk factors - known 'prior to stroke 
Past Hypertension 
Known diabetes 




BP on admission: 
Complications: I 
Adm 1 week 
• 
pneumonia: 0 yes 0 no 
lITl 0 yes 0 no 
OVTorPE 0 yeo Ono 
seizures 0 yes 0 no 
depreSSion 0 yes 0 no 
bedsores 0 Y'" 0 no 
worsening stroke 0 yes 0 no 
(symptoms and signs evolve over hours) 












Type 01 Slroke 
DnA o Haemontlage o Ischaemlc Inlarct 
o uncertain (no Cn 
Localisation at lsctIaemic stroke: 
0 complete anterior circulation 




Localization ot heemontlage 
o cortical lobar 


























FBe: Olormal o abnormal - specify: 
ESR or blood viscosity: O1ormal o abnormal - specify: 
Urea/creatlnine/elecs: Dnocmal o abnormal - specify: 
Blood glucose (on admission): o normal o abnormal - specify: 
HIV: o not done Onegative o positive 
VORL o not done o negative o positive 
hypercoag screen: 0 not done o negative o positive - specify: 
antiphosphollpid Ab:O not done o negative o positive - specify: 
collagen screen: o noldone Ononnal o abnormal - specify: 
lipids: CJ nol done o normal o abnormal - specify: 
- -
CSF: o noldene o normal o abnormal - specify: 
ECG: o not done o normal o abnormal - specify: 
-
Radiology: 
CXR: o not done o normal o abnormal - specify: 
." 
CThead: o not done o normal · Oabnormal-sp~ .. 
cerebral angio: o not done o normal o abnormal - specify: 
MRI head: o not done D normal Oabnormal - specify: 
" 
MRAhead: o not done o normal D abnormal - specify: 
Carotid duplex o not done Dnormal o abnormal - specify : 
dopplers: % occlusion lett _ % occlusion right 
dissection: Dye. Dna 
transcranial dopplersDnot done o normal Oabnormal - specify : 
Cardiac echo: o noldone o normal Oabnormal - specify: 
(Transthoracic) o intracavity clot Odyskinetie segment DR to lshunt 
o valvular lesion other: 
Transoesophageal 0 not done o normal Oabnormal - specify: 
Cardiac echo: o intraeavity clot D dyskinetic segment DR to l shunt 
o valvular lesion other. 
Other relevant investigations: 
Medication prior to stroke: Was patient independent on AOl prior 10 
Oantiplatelet o heparin D warfarin admission? 0 yes Dna 













. Aetiology of Ischaemic stroke : 
o lallie vessel atherothromboembollc: 0 pn>babIe 
o eardiO<lmbollc: 0 probable 
o Small vessel (lacunar): 0 probable 
Dpossibla 
Dpossible 
o possible o Acute Ischaemic sttoke of other aetiology· speCifY:~::-:::::;::::::;:-_________ _ 
o Acute Ischaemic stroke of unknown cause (incomplete workup) o Acute Ischaemic stroke or unknown cause (no probable aetiology despite complete wortup) 
D Acute Ischaemlc stroke of unknown aetiology (mo~ than one likely aetiology and a single likely 
aetiology cannot be determined) specify: ______________ _ 
Aetiology of inncerebral haemorrhage: 
T~tment 
o Aspirin o asptrin • dipyridamole o uCtOpidlne o cIopIdogrol 
D Heparin prophylactic dosage 0 hapadn full dosage 
D Warfarin 
o Oxygen DAnilbiotics . DAnII~IICS Dlnsulln o Antlhypert.~e meds 
o SUrge<)': 
o Thrombolysis - specify thrombolytic age.n!: 
Route of adminiStration: 0 intravenous Dlntnl-artef'ial 
tOlal dose: 
TIme interval (stroke onset to Infusion): 
Complications; []symptomatic Intracerebral haernon11age o asympl intracerebral haemon11age 
Dextracnlnial haemontlage -o Neuroprotective agents: specify agent: total dOH: Route of admlnlstralio": Oral 0 M 




Duration of hospilllUzatfon: 
o admissJon ward - duration: 
D leu • duration: 
o Medical ward . duration: 
D Stroke Unn - duration: 
D Otherward - duration: 
TOTAL duration of hospital stay: 
Death: 0 yes D no cause of death: 








Special case: 0 Ves D No 
Comments: 
DATE OF DISCHARGE: 1L.-'---.l._L--'---'---' 
dfsCtlarge to: Ohoma care o rehabillitation centre Dother.. ____ _ 
Home carer available: Dno 0 yes - It yes specifyD partner 0 other: 











5.2 Appendix B: Consent form 
 
CONSENT FORM TO RECEIVE THROMBOLYTIC TREATMENT WITH 
TISSUE PLASMINOGEN ACTIVATOR (TPA) FOR ACUTE ISCHAEMIC 
STROKE 
I understand that my doctors believe that I have suffered a stroke. They also 
believe that I may benefit from treatment with TPA. 
Recent medical research suggests that some patients will benefit significantly 
from this treatment. Specifically, patients receiving TPA have a 30% better 
chance, three months after their strokes, of having minimal or no disability. 
I understand that TPA treatment has risks. Research indicates a 6.4% 
chance of brain haemorrhage in patients receiving this treatment as compared 
to 0.6% of patients not receiving this treatment. Brain haemorrhage, if it 
occurs can resu~ in a significant worsening of my stroke symptoms, may 
increase my ultimate disability, and may result in my death. TPA can also 
cause haemorrhaging elsewhere in the body, such as the intestines, kidneys 
or other organs. 
I have read the above information and understand the potential risks and 
benefits of TPA therapy for my condition. I wish to proceed with TPA 
treatment as described by my physician. 












5.3 Appendix C: TOAST classification 
 


















Palient ldentification __ . ___ . __ _ 
PI. Dateof Birth __ '__ , __ 
Hospital ______ --'L_-_-1 
Date of Exam __ , __ , __ 
Interval: [ [ Baseline [ [ 2 hours posttreatment [ J 24 hours post onset of symptoms ±20 minutes [ )7-10 days 
[ ]3 months II Other L _ ) 
Time: __ : __ [Jam [ Jpm 
Person Administering Scale _____________ _ 
Administer stroke scale items in the order listed. Record pelformance in each category after each subscale exam. Do not go 
back and change scores. Follow directions provided for each exam technique. Scores should reflect what the patient does, not 
what the clinician th inks the patient can do. The clinician should record answers while administering the exam and work quickly_ 
Except where indicated, the patient should not be coached (Le., repeated requests to patient to make a special effort). 
Instructions Scale Defin ~ion Score 
1 • . Level of Consciousness : The ilveslgator must ctoose a o~ Alert; keOOy responsive. 
response ~ a full evaluation is prevooted by such obstacles as an 1 ~ Not alert; oot arousable by moor stimLiation to r:bey, 
endotracheal tube, language barrier, orotracheal traumalbandages. A answer, or respond 
3 is scored only ~ the patient makes no rrovement (othef than rellexive 2 ~ Not alert; requires repeated stimulation to atteod, or is 
posturing) n response to ooxious sfrnulation. obtlJlded <rid requires strong or painful stmulation to --
make roovements (not stereotyped). 
3~ Responds only with rellex rootor or autonomic effects or 
totally unresponsive, tlaccid, and areflexic. 
1 b. LOC Questions : The patient is asked the fOCIIlth and hislher age. O~ Answers both Questiorls correctly. 
The answer must be correct - there is no partial credit for being dose. 
Aphasic and stlfjOlOOS patients '/tOO do not comprehend the questions 1 ~ Answers one question correctly. --
will score 2 Patients unable to speak because of endotracheal 
intubation, orotrocheal trauma, severe dysarthria from any cause, 2~ Answers neither Question correctly. 
language barrier, or any other problem not secondary to aphasia are 
given a 1. It is important that only the initial answer be graded and that 
the examnef not "help. the patient with verbal or non-verbal cues. 
1c. LOC Commands: The patient is aslled to open and dose the o = Performs both tasks correctly. 
eyes and then to grip and release the non-paretic hand. Substitute 
another one step command if the halds cannot be used. Cred:t is 1 = Performs one task correctty 
given if ~ uneqLivoca[ attempt is made but not completed We to 
weakness. If the patient doos not respond to command, the task 2 = Performs neither task correctty. --
shoold be demonstrated to him or her (pantomime), and the resLit 
scored (Le., folows none, one or two comnmds). Patients v.ith 
trauma, amputation, or other physical impediments shoold be given 
suitable ooe-step commands. Only the first attempt is scored 
2. Best Gaze: Only horizontal eye roovements will be tested. 0 = Normal. 
Voluntary or reflexive (oculocephalic) eye movements will be scored, 
but caloric testing is not done If the patient has a conjugate 1 = Partial gaze palsy; gaze is abnormal in one or both eyes, 
deviation of the eyes that can be overcome by voluntary or reflexive but forced deviation or total gaze paresis is oot preseot. --
activity, the score will be 1. If a patient has an isolated peripheral 
nerve paresis (CN [II , [V or VI), score a 1. Gaze is testable in all 2 = Forced deviation, Of total gaze paresis not overcome by the 
aphasic patients. Patients with ocular trauma, bandages, pre-existing oculocephalic maneuver. 
blindness, or other disorder of visual acuity or fields should be tested 
with reflexive movements, and a choice made by the investigator 
Establishing eye contact and then moving about the patient from side 

















Palient ldentification __ -___ -__ _ 
PI. DateofBirth __ '__ I __ 
Hos.~I _______ \L_-_~ 
Date of Exam __ , __ , __ 
Interval: [1 Baseline []2 hours post treatment [ ) 24 hours post onset of symptoms ±20 minutes [ J7-tOdays 
[J3 months [) Other __________ L _ ) 
3. Visual: Visual fields (upper and lower quadrants) are tested by o = No visual loss. 
confrontation, using finger counting or visual threat, as appropriate. 
Patients may be encouraged, but if they look at the side of the 1 = Partial hemianopia. 
moving fingers appropriately, this can be scored as normal. If there is --
unilateral blindness or enucleation, visual fields in the remaining eye 2 = Complete hemianopia. 
are scored. Score 1 only if a dear-eut asymmetry, including 
quadranlaoopia, is found. If patient is blind from any cause, score 3. 3 = Bilateral hemianopia (blind including cortical blmness). 
Double simultaneous sbmulation is performed at this point. If there is 
extinction, patient receives a 1, and the results are used to respond to 
item 11 . 
4. Facial Palsy: Ask - or use pantomime to encourage - the patient o = Normal symmetrical movements 
to show teeth or raise eyebrows and close eyes. Score symmetry of 1 = Minor paralysis (flattened nasolabial fold, asymmetry on 
grimace in response to noxious stimuli in the poorty responsive or smi.ng) 
non-comprehending patient If facial traumalbandages, orotracheal 2 = Partial paralysis (total or near-total paralysis at lower --
tuba, tape or other physical barriers obscure the face, these shoold face). 
ba removed to the extent possible. 3 = Complete paralysis at one a both sides (absence of 
fadal movement in the upper and lower face). 
5. Motor Arm: The limb is placed in the appropriate position: extend o = No drift ; limb holds 90 (or 45) de!1ees for f[j110 seconds 
the arms (palms down) 90 degrees (if sitting) a 45 degrees (if 1 = Drift; lini> holds 90 (or 45) del}"ees, rut drifts down before 
supine). Drift is scored if the arm falls before 10 seconds. The full 10 secoods; does not hit bed or other support. 
aphasic patient is encouraged using urgency in the voice and 2 = Some effort against gravity; 1mb cannot get to or 
pantomime, but not noxious stimulation. Each limb is tested in tum, maintain (if cued) 00 (or 45) degrees, drifts down to bed, 
beginning with the non-paretic arm. Only in the case of amputation or but has some effort against gravity 
joint fusion at the shoulder, the examiner should record the score as 3 = No effort against gravity; limb falls 
untestable (UN), and clearty write the explanation for this choice 4 = No movement. 
UN = Amputation or joint fusioo, explain· 
s.. Left Arm --
5b. Righi Arm --
6. Motor Leg: The limb is placed in the appropriate position: hold o = No drift ; leg holds 3O-degree p:lSiOOn fa MIS secoods 
the leg at 30 degrees (always tested supine). Drift is scored if the leg 1 = Drift ; leg falls by the end at the 5-second period but does 
falls before S seconds. The aphasic patient is encouraged using not hit bed 
urgency in the voice and pantomime, but not noxious stimulation 2 = Some effort against gravity; leg falls to bed by S 
Each limb is tested in tum, beginning with the non-paretic leg. Only seconds, but has some effort against gravity 
in the case of amputation or joint fusion at the hip, the examiner 3 = No effort against gravity; leg falls to bed immediately 
should record the score as untestable (UN), and clearty write the 4 = No movement. 
explanation for this choice UN = Amputation or joint fusioo, explain· 
6 •. Left Leg --
















Patient Identification. __ -___ -__ _ 
PI. DateofBirth __ '__ , __ 
Hospitlll _______ L_-_~ 
Date of Exam __ , __ , __ 
Interval: [[ Baseline [[ 2 hours post treatment [) 24 hours post onset of symptoms ±20 minutes [ )7-10days 
[ ) 3 months II Other __________ ,L _ l 
7. Limb Ataxia: This item is aimed at finding evidence of a unilateral 
cerebellar lesion. Test with eyes open. In case of visual defect, 
ensure testing is done in intact visual ftekl. The finger-nose-finger 
and heel-shin tests are performed on both sides, and ataxia is scored 
only if present out of proportion to weakness. Ataxia is absent in the 
patient who cannot understand or is paralyzed. Only in the case of 
amputation Of joint fusion, the examiner should reaJ(d the score as 
untestable (UN), and clearly write the explanation for this choice. In 
case of blindness, test by having the patient touch nose from 
extended arm position. 
8. Sensory: Sensation or grimace to pinprick l'Jlen tested, Of 
withdrawal from noxious stimulus in the obtunded or aphasic patient 
Only sensory loss attributed to stroke is scored as abnormal and the 
examiner should test as many body areas (anns [not hands!, legs, 
trunk, face) as needed to accurately check for hemisensory loss. A 
score of 2, 'severe or total sensory loss,' should only be given when 
a severe or total loss of sensation can be clearly demonstrated. 
Stuporous and aphasic patients will , therefore, probably score 1 or 0 
The patient with brainstem stroke who has bilateral loss of sensation 
is scored 2. If the patient does not respond and is quadriplegic, score 
2. Patients in a coma (item 10=3) are automatically given a 2 on this 
item. 
9. Best Language: A great deal of information about comprehension 
will be obtained during the preceding sections of the examination 
For this scale item, the patient is asked to describe what is happening 
in the attached picture, to name the rtems on the attached naming 
sheet and to read from the attached list of sentences 
Comprehension is judged from responses here, as well as to all of 
the commands in the preceding general neurological exam. If visual 
loss interferes with the tests, ask the patient to identify objects placed 
in the hand, repeat, and produce speech. The intubated patient 
should be asked to write. The patient in a coma (item la=3) will 
automatically score 3 on this item The examiner must choose a 
score for the patient with stupor or limrted cooperation, but a score of 
3 should be used only if the patient is mute and follows no one-step 
commands. 
10. Dysarthria: If patient is thought to be normal, an adequate 
sample of speech must be obtained by asking patient to read or 
repeat words from the attached list. If the patient has severe 
aphasia, the darity of articulation of spontaneous speech can be 
rated. Only if the patient is intubated or has other physical barriers to 
producing speech, the examiner should record the score as 
untestable (UN), and clearly write an explanation for this choice. Do 
not tell the patient why he or she is being tested. 
0= Absent. 
1 = Present in one limb. 
2 = Present in two limbs. 
UN = Amputation or joint fusion, explain: _____ _ 
o = Normal; 00 sensory loss. 
1 = Mild·to-moderate sensory loss; patient feels pin!X"iCk is 
less shllp or is dull on the affected side; Cl there is a 
loss of superficial pain with pinplick, but patioot is av.rare 
of being touched. 
2 = Severe to total sensory loss; patient is not aware of 
being touched in the face, arm, and leg 
o = No aphasia; normal 
1 = Mild-to-moderate aphasia; some obvious loss of fluency 
or facility of comprehenSion, without significant 
limitation on ideas expressed or form of expression 
Reduction of speech and/or comprehension, however, 
makes conversation about provided materials difficult 
or impossible. For example, in conversation about 
provided materials, examiner can identify picture or 
naming card content from patient's response 
2 = Severe aphasia; all commlflication is through fragmentary 
expression; great need for inference, questioning, and guessing 
by the listener. Range of information that can be excha[)Jed is 
limited; listener carnes burden of communication. Exanlner 
cannot identify materials provided from patient response. 
3 = Mute, global aphasia; 00 usable speech or aOO:te»y 
comprehension. 
0= Normal. 
1 = Mild-to-moderate dysarthria; patient sllrs at least some 
'NClrds 000, at 'NOrSt, can be uooarstood v.ith some 
diffiOJlty. 
2 = Severe dysarthria; palienrs speech is so slurred as to be 
lflintelligible in the absence of or out of propation to 
any dysphasia, or is mutelanartliic. 


































Patienl ldentification __ -___ -__ _ 
Pt. DateofBirth __ '__ I __ 
Hospital _______ \L __ ~ 
Date of Exam __ , __ , __ 
Interval: I J Baseline I J 2 hours post treatment I J 24 hours post onset of symptoms ±20 minutes 1]7-10 days 
1]3 months II Other __________ L _ l 
11. Extinction and Inattention (formerly Neglect): Sufficient o = No abnormality. 
information to identify neglect may be obtained duri l"lQ the prior 
testing. If the pabent has a severe visual loss preventing visual 1 = Visual, tactile, aud~ory, spatial, or personal inattention 
double simultaneous stimulation, and the cutaneous stimuli are or exiincOOn to bilateral siOl.lltaneoos stimulatioo in one --
normal, the score is normal If the patient has aphasia but does of the sensory modalities 
appear to attend to both sides, the score is normal. The presence of 
visual spatial neglect or anosagnosia may also be taken as evidence 2 = Profound hemi-inattenlion or extinction to more than 
of abnormality. Since the abnormality is scored only if present, the one modality; does not recognize own hand or OIients 











5.6 Appendix F: Stroke Unit thrombolysis inclusion and exclusion criteria 
RECOMMENDATIONS FOR THE USE OF INTRAVENOUS t-PA 
FOR TREATMENT OF ACUTE ISCHAEMIC STROKE 
UCT STROKE UNIT 
PATIENT SELECTION CRITERIA: 
Inclusion Criteria: 
1. Age> 18 and < to 75. Yes No 
2. Clinical diagnosis of acute ischaemic stroke causing a new 
measurable deficit defined as impairment of motor function, 
language, cognition and/or gaze, vision or neglect. Yes No 
3. Time of onset well established to be less than 270 minutes 
before treatment would begin. Yes No 
4. CT Scan or MRI Scan performed and read. Yes No 
5. Bloods drawn and lab results reviewed 
(Full Blood Count, Glucose and Electrolytes, PT, PTT, 
INR). Yes No 
Exclusion 
1. Patient has: (a) only minor symptoms of stroke Yes No 
(NIH stroke score < 4) 
(b) major symptoms that are rapidly im-
proving by the time of onset of treat-
ment Yes No 
2. Patient is comatose. Yes No 
3. CT Scan shows (a) evidence of intracranial haemorrhage Yes No 
(of any degree or location) 
b) Coincidental or causal intracranial 
tumours (except small meningiomas). Yes No 
(c) ischaemic infarcts with significant 
mass effect with midline shift Yes No 
4. Patient has a clinical presentation that suggests sub-
arachnoid haemorrhage even if the initial CT Scan is 
normal. Yes No 
5. Patient known to have aneurysm, or arteriovenous 
malformation. 
6. Patient is female and lactating or known or suspected to 





















































5.7 Appendix G: SYNOPSIS (prepared for lay persons as per UCT HREC requirements) 
Project title 
Early outcomes of thrombolysis for acute ischaemic stroke in a South African tertiary 
care centre 
 
Background and rationale for study 
Stroke is a growing problem in sub-Saharan Africa and is a leading cause of disability 
and death in the region. Until recently there has been no specific cure for stroke, and 
the management has focused on prevention and supportive care. Ischaemic-type 
strokes are caused by sudden obstruction of an artery in the brain by a blood clot, 
called a thrombus. These clots either arise from distant sites such as the heart or 
carotid arteries in the neck, or form in situ on an already diseased cerebral artery. 
There are certain drugs that have the ability to dissolve newly-formed thrombi, a 
process known as thrombolysis. These thrombolytic drugs work by mimicking and 
exaggerating the physiological process of clot dissolution. It was hypothesised that 
they could be used early in the course of ischaemic strokes to open the occluded 
artery in order to re-perfuse and salvage affected downstream brain tissue. 
However, thrombolytic agents are usually administered intravenously and their site 
of action is not specific. They thus have the potential to cause life-threatening 
bleeding both at distant sites and intracranially, a feared and real complication of 
their use.  
 
Thrombolytic therapy for acute ischaemic stroke has been thoroughly tested in both 
controlled and open-label trials which have consistently shown benefit for its use up 
to 4.5 hours after the onset of stroke symptoms. The only drug approved for this is a 
recombinant tissue plasminogen activator (tPA) called alteplase. Patients receiving 
alteplase are 30% more likely to survive with minimal disability and have a 12% 
absolute greater chance of achieving excellent functional outcomes at 3 months. 
Although this intervention does come at the cost of significantly increased risk of 
intracranial bleeding compared with placebo, thrombolysis has no impact on overall 












There are a number of limitations to the widespread use of thrombolysis. Firstly, all 
patients require a CT scan prior to treatment to ensure that there is no pre-existing 
intracranial bleeding. Second, the benefits of alteplase are inversely related to the 
time of infusion after stroke symptom onset, and its administration beyond 270 
minutes may be harmful. Thus potential candidates need to arrive at an equipped 
hospital early after their stroke in order to access this treatment. These inherent 
limitations impose significant barriers to thrombolysis, especially in resource-poor 
developing countries. 
 
Despite the above concerns, a number of studies have demonstrated equivalent 
safety and efficacy of thrombolysis in developing countries. However, there is no 
published data on the feasibility of this important intervention in an African setting. 
We therefore seek to investigate whether tPA can be safely used in routine practice 
at a tertiary stroke referral centre in South Africa, and if this results in the early 
neurological improvement seen with its use in other settings. In order to determine 
this, we will analyse efficacy and safety outcome data prospectively entered into the 
UCT Stroke Database over the past 11 years. Our findings will be compared with 
published results of trials and large observational studies from developed countries 
as well as with those from open-label use in developing regions. We also hope to 
identify potential factors that limit the application of this therapeutic option and 
ways in which it may be improved.  
 
Patients, recruitment and eligibility 
This analysis will include all patients who received alteplase at Groote Schuur 
Hospital (GSH) over the period January 2000 to March 2011. GSH is a tertiary referral 
centre in the Western Cape, but also provides secondary level care for patients living 
in its direct drainage areas; it thus receives referrals from other centres as well as 
self-referrals. The hospital supports a community of predominantly low to middle 
socio-economic status from an urban environment. In this population there appears 
to be a high prevalence of risk factors for cerebrovascular disease, such as diabetes 












Patients are recruited by virtue of being selected to receive thrombolysis according 
to the Stoke Unit Protocol criteria, and their clinical details are prospectively 
captured in the UCT Stroke Database. Men and women between the ages of 18 and 
75 years with a clinical diagnosis of acute stroke and certain time of onset within the 
preceding 4.5 hours are potential candidates. Eligibility for intravenous thrombolysis 
is assessed by the neurology or ‘stroke’ registrar on call in consultation with an 
attending neurologist. Patients receiving intra-arterial tPA are also included in the 
analysis, and the decision to use this route of administration is made in each case by 
a neurologist together with a neurosurgeon.  
 
Exclusion criteria are clearly defined by the existing GSH Stroke Unit guidelines 
(protocol appendix F) which are based on those used in the NINDS-tPA trial. 
Contraindications to thrombolysis broadly include any evidence of intracranial 
haemorrhage on brain imaging, depressed level of consciousness or rapidly 
improving symptoms, a history of stroke within the receding 3 months, and a high 
risk of bleeding.  
 
Informed consent and privacy  
The use of tPA for thrombolysis in selected patients with acute ischaemic stroke is 
considered to be standard of care, and has been endorsed in recently published 
stroke management guidelines by the South African Stroke Society. This survey does 
not involve randomisation or control substances, and patients are informed of the 
risks and benefits of the intervention during the consent process. Participation in this 
observational study is dependent on the patient consenting to the treatment on its 
own merits and in no way influences the management decisions taken with regard to 
individual patients. The alternative to this intervention includes the same stroke care 
provided to those patients who do not otherwise qualify for thrombolysis. 
 
In all cases informed consent for the use of tPA is obtained before the therapy is 
administered. In cases where the patient lacks capacity to consent, consent is 
obtained from a suitable relative as per standard hospital guidelines. The consent 











documented on a specifically designed form which also includes an explanation of 
the risks and benefits of the intervention (included in protocol Appendix B). 
 
Personal and medical information of the participants is only accessible to the 
attending doctors and the study investigators. All names are erased and variables 
have been coded in the dataset used for statistical analysis. The UCT Stroke 
Database is only accessible to the investigators. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
